Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
09/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions September class, title,number 09/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
09/30/2010 > patent applications in patent subcategories. class, title,number

20100249015 - Use of vegf in the treatment of retarded fetal growth in pregnancy: An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a peptide.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100249018 - Composition and method for preventing and treating immune-related disorder: The present invention relates to an immunoregulating agent comprising a peptide, a pharmaceutical composition and a method of preventing or treating immune-related disorder such as sever sepsis or acute respiratory distress syndrome (ARDS), and the use of peptide for anti-inflammatory agent, an antibacterial agent, or an inhibiting agent of an... Agent: LexyoumeIPGroup, LLC

20100249016 - Metal-binding compounds and uses therefor: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further... Agent: Sheridan Ross PC

20100249017 - Use of cnp-22, alone or in combination with physalemin, as a therapeutic agent: The present invention is directed to the use of the peptide compound Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100249019 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the combination of the peptide compounds Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-OH and VaI-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.... Agent: Winstead PC

20100249020 - Fast-acting insulin formulation: The invention relates to a complex between an insulin and a polysaccharide comprising carboxyl functional groups, said polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, said phenylalanine derivative being chosen from the group consisting of phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide... Agent: Oliff & Berridge, PLC

20100249021 - Method and medicament for inhibiting the infection of influenza virus: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and... Agent: Knobbe Martens Olson & Bear LLP

20100249022 - Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins: The present invention relates generally to soluble G protein-coupled receptor constructs. More specifically, the invention relates to soluble chemokine receptors, and soluble HIV co-receptors in particular. The invention is generally useful for designing and constructing soluble GPCR, which may be used to identify binding molecules. The invention also relates to... Agent: Wolf Greenfield & Sacks, P.C.

20100249023 - Isoflavone formulation: This invention relates to the formulations of isoflavones with soluble carrier proteins, for example whey proteins. The formulations display increased lipid modulating activity without increased estrogenic activity, relative to isoflavone alone and may be useful, for example in therapeutic applications, such as the treatment of metabolic dysfunction, cancer and skin... Agent: Klarquist Sparkman, LLP

20100249024 - Cetp inhibitors: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused... Agent: Merck

20100249025 - Peptide antagonists of vascular endothelial growth factor: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and... Agent: David S. Resnick

20100249026 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100249027 - Crf conjugates with extended half-lives: The present invention relates to conjugates of CRF that have been modified to include a moiety that protects CRF from degradation and prolongs the half-life of CRF. The CRF conjugates of the invention have an increased half-life which results in a dose-sparing effect and less frequent administration... Agent: Jones Day

20100249030 - Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment: The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inhibitors that are useful in the inventive treatment.... Agent: Merck Patent Department (k-6-1, 1990)

20100249031 - Nutritional composition comprising curcuminoids and methods of manufacture: Disclosed are nutritional compositions and methods for preparing the compositions, comprising fat, protein, and carbohydrate, including a combination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin, which combination is solubilized in a polar oil having an HLB value of from about 0.7 to about 14 wherein the weight ratio of the bisdemethoxycurcumin to... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20100249028 - Oral composition: An object of the present invention is to provide an oral composition useful for promoting collagen synthesis and the like. The present invention can provide an oral composition containing collagen or gelatin or a degradation product thereof, and hydroxyproline or a salt thereof. The weight ratio of alanine and hydroxyproline... Agent: Leydig Voit & Mayer, Ltd

20100249029 - Peptides with high affinity for the prolactin receptor: The invention relates to variants of prolactin, which variants have high affinity for the prolactin receptor.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100249032 - Human epo mimetic hinge core mimetibodies, compositions, methods and uses: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors,... Agent: Philip S. Johnson Johnson & Johnson

20100249033 - Polymer factor ix moiety conjugates: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the... Agent: King & Spalding LLP

20100249034 - Gfralpha3 and its uses: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFRα3, a novel α-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an α-subunit... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100249035 - Peptides, compositions and uses thereof: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100249036 - Method for treating depression: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.... Agent: Klarquist Sparkman, LLP

20100249037 - Animal model for infant pathologies: A method of providing an animal model for at least one infant pathology, including delivering an animal prior to full physical development; performing a surgical procedure on the animal to provided capacity for respiratory assistance and nutrition; exposing the animal to varying concentrations of oxygen; and optionally repeating the exposure... Agent: Waddey & Patterson, P.C.

20100249038 - Antagonists of the receptor for advanced glycation end-products (rage): Novel peptides are useful as antagonists of RAGE and may be used to treat cancer, inflammation, diabetes and arthritis through the administration of a therapeutically effective amount of the peptide to a subject in need thereof.... Agent: NielsenIPLaw LLC

20100249039 - Methods for treating cancer using an immunotoxin: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific... Agent: Dann, Dorfman, Herrell & Skillman

20100249040 - Alpha-fetoprotein peptides and uses thereof: Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249042 - Compositions and methods for treatment of eyelashes and eyebrows: The fullness and length of eyelashes and eyebrows can be enhanced by topical application of a composition comprising at least one peptide copper complex to an area of skin at the base of the eyelashes and eyebrows. Disclosed are compositions and methods for such treatment.... Agent: Seed Intellectual Property Law Group PLLC

20100249041 - Compositions comprising ornithine ketoglutarate (okg): Suggested are new compositions comprising Ornithine Ketoglutarate (OKG) and a cosmetically acceptable carrier the latter selected from the group consisting of aliphatic alcohols or polyols having 2 to 15 carbon atoms or oil bodies.... Agent: Dilworth & Barrese, LLP

20100249043 - Compositions and methods for promoting hair growth: (d) 0.03 to 1.8 wt %, preferably 0.03 to 0.3 wt % of one or more sulfur-rich amino acids on the basis of the total weight of the said composition. The composition and method are capable of making hair much longer and thicker in relatively shorter time without any serious... Agent: Joseph L. Strabala, Esq.

20100249044 - Biogel: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localised drug delivery.... Agent: Seed Intellectual Property Law Group PLLC

20100249045 - Multimodal abuse resistant and extended release opioid formulations: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the... Agent: Flaster/greenberg P.C. Four Penn Center

20100249046 - Novel mangiferin calcium salts, the method for its preparation and its use: The present invention relates to novel mangiferin calcium and its preparation and use. The mangiferin calcium can lower plasma insulin, glucose, lipid, also can improve the solubility and oral bioavailability of mangiferin.... Agent: Birch Stewart Kolasch & Birch

20100249049 - Arylalkylamine compound and process for preparing the same: e

20100249048 - Beta glycolipids for the treatment of calcification related degenerative disorders: The present invention relates to a composition comprising a combination of at least one natural or synthetic β-glycolipid, a mixture of at least two β-glycolipids, a substance which increases the intracellular, extracellular or serum level of a naturally occurring β-glycolipid, or any combination or mixture thereof and at least one... Agent: Alston & Bird LLP

20100249047 - N-acetyl mannosamine as a therapeutic agent: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.... Agent: Klarquist Sparkman, LLP (ott-nih)

20100249050 - Epothilone glycoside and use thereof: e

20100249051 - Bioactive molecules from co-cultivation of microbes: Certain aspects of the invention relates to antibiotics, as well as pharmaceutically acceptable salts, pro-drugs and/or analogs thereof. Another aspect of the inventions relates to methods of use of said antibiotics.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100249052 - Dsrna compositions and methods for treating hpv infections: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of... Agent: Alnylam/fenwick

20100249209 - Gene involved in immortalization of human cancer cell and use thereof: The present invention provides a gene related to cancer cell immortalization (an immortalization determining gene) and a process that is useful for selective cancer treatment targeting a cancer cell having the gene. The present invention determines an immortalized cancer cell using a polynucleotide having a base sequence of at least... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100249212 - Gene silencing using mrna-cdna hybrids: The present invention provides novel compositions and methods for suppressing the expression of a targeted gene using mRNA-cDNA duplexes. The invention further provides novel methods and compositions for generating amplified mRNA-cDNA hybrids, whose quantity is high enough to be used for the invention's gene silencing transfection. This improved RNA-polymerase chain... Agent: Hogan Lovells US LLP

20100249210 - Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration: Disclosed are compositions and methods for treating neurodegenerative disease.... Agent: Ballard Spahr LLP

20100249213 - Microrna signatures in human ovarian cancer: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of ovarian cancer. The invention also provides methods of identifying anti-cancer agents.... Agent: Macmillan Sobanski & Todd, LLC

20100249214 - Multiplex dicer substrate rna interference molecules having joining sequences: The present invention is based, at least in part, upon the insight that compound DsiRNA agents can be generated using site-specific RNase H-cleavable double stranded nucleic acid double stranded nucleic acid regions to attach, e.g., one DsiRNA moiety to another DsiRNA moiety and/or one DsiRNA moiety to a functional group... Agent: Edwards Angell Palmer & Dodge LLP

20100249211 - N-substituted-aminomethylene bridged bicyclic nucleic acid analogs: Provided herein are bicyeMc nucleosides comprising a substituted amino group in the bridge, oligomeric compounds having at least one of these bicyclic nucleosides and methods of using the oligomeric compounds. The bicyclic nucleosides comprising a substituted amino group in the bridge are useful for enhancing properties of oligomeric compounds including... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100249208 - Novel methods and models for rapid, widespread delivery of genetic material to the cns using non-viral, cationic lipid-mediated vectors: Provided are safe, non-invasive, non-viral delivery methods for providing a nucleic acid into the neuronal and non-neuronal cells of the central nervous system (CNS) of a subject to protect neuronal and non-neuronal cells from ischemic or traumatic injury, wherein the nucleic acid encodes a therapeutic proteins, specifically providing rapid transient... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20100249215 - Oligomeric compounds and compositions for use in modulation of pri-mirnas: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided... Agent: Pepper Hamilton LLP

20100249220 - Coumermycin/novobicin-regulated gene expression system: A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the... Agent: Cassan Maclean

20100249221 - In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13... Agent: Morris Manning Martin LLP

20100249216 - Method for the production of a cell and/or tissue and/or disease phase specific medicament: The invention relates to a method for the production of a cell and/or tissue and/or disease phase specific medicament against chronic inflammatory diseases. Disease, cell-type, tissue and/or stage specific proteins and nucleic acids are identified with regard to the modified expression pattern and the corresponding nucleic acids are analyzed as... Agent: Kf Ross PC

20100249218 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or... Agent: Howrey LLP - East

20100249217 - Modulators of pharmacological agents: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves,... Agent: King & Spalding

20100249219 - Short rna antagonist compounds for the modulation of hif-1alpha: The present invention relates to oligomeric compounds (oligomers) of 12, 13 or 14 nucleotides in length, which target Hif-1alpha mRNA in a cell, leading to reduced expression of Hif-1alpha. Reduction of Hif-1alpha expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative disorders, such as cancer.... Agent: Dechert LLP

20100249053 - Method for inducing hepatocyte proliferation and uses thereof: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR... Agent: Buchanan, Ingersoll & Rooney PC

20100249055 - Clofarabine phospholipid derivatives: The subject of the present invention are specific phospholipidesters of clofarabine and the use of such lipidesters in the treatment of tumors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100249054 - Purine nucleoside derivative modified in 8-position and medical use thereof: In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20100249056 - Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates: The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular viral infections, cancers and the like.... Agent: Swanson & Bratschun, L.L.C.

20100249058 - Feed additive and feed: To provide safe and easy means for preventing or treating diseases of birds and mammals, in particular, livestock. In particular, to provide means for preventing or treating an infectious disease caused by a Gram-positive bacterium. In addition, to improve fermentation in the rumen of a ruminant animal, to contribute to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100249057 - Trehalose compound and pharmaceutical comprising the compound: wherein X and X′ represent a hydrogen atom, and the like; Y and Y′ independently represent an oxygen atom, and the like; R1 and R2 independently represent a C1-C6 alkyl group; and R3 and R4 independently represent a C3-C6 alkyl group. The trehalose compound of the present invention has a... Agent: Kratz, Quintos & Hanson, LLP

20100249059 - Bone filling complex and method for fabricating the same: Provided is a bone filling complex and a method of preparing the same. The bone filling complex includes a matrix including a hydrogel-type hyaluronic acid derivative; and a bone derivative filling the matrix, and thus adhesion can be prevented and excellent bone generation property can be obtained. For example, the... Agent: Cantor Colburn, LLP

20100249060 - Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes: A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with the mouth, such... Agent: Lynn E Barber

20100249061 - Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same: The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100249063 - Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same: [Means for Solving Problems] Disclosed is, for example, an amorphous body of a heterocyclic compound as represented by the general formula (I) [wherein each of R's and others is as defined in the description] including s-triazine and a pyrimidine derivative, or a hydrate, a solvate or a pharmaceutically acceptable salt... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100249062 - Ophthalmic composition: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention... Agent: Birch Stewart Kolasch & Birch

20100249064 - Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan: The present invention concerns methods and compositions involving hyaluronan that has been substantially purified to enrich for hyaluronan with a molecular weight above 500 kilodaltons. This hyaluronan can be used for diseases and conditions characterized or caused by increased vascular permeability or angiogenesis. The higher molecular weight hyaluronan restores vascular... Agent: Fulbright & Jaworski L.L.P.

20100249065 - Biomarkers for assessing peripheral neuropathy response to cancer treatment: The present invention provides methods for identifying patients at increased risk of developing an adverse neurological event in response to a cancer treatment. Methods also include modifying the treatment regimen of said patent dependent on the presence or absence of biomarkers in the patient.... Agent: Philip S. Johnson Johnson & Johnson

20100249066 - Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition,... Agent: Jones Day

20100249067 - Modulators of mitotic kinases: The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100249068 - Substituted nucleoside and nucleotide analogs: Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates.... Agent: Knobbe Martens Olson & Bear LLP

20100249070 - Active compound combinations having insecticidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, anthranilamides (group 1) and, secondly, further insecticidal active compounds selected from the group of the (thio)phosphates (group 2) and/or the group of the carbamates (group 3), which combinations are highly suitable for controlling animal pests, such as insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100249069 - S1p3 receptor inhibitors for treating pain: Disclosed herein are compositions and methods for treating pain using S1P3 receptor inhibitors.... Agent: Allergan, Inc.

20100249071 - Modulators of s1p and methods of making and using: s

20100249072 - Prodrugs and conjugates of prenylation inhibitors: Described herein are neutral prodrugs of phosphorus-containing inhibitors of farnesyl transferase that include one or more phosphate fragments or analogs of phosphate fragments. Analogs of phosphate fragments include various linkers other than oxygen connecting the phosphate fragment to the remaining portion of the drug, such as but not limited to... Agent: Barnes & Thornburg LLP

20100249073 - Prophylactic and therapeutic treatment of alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein: A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid... Agent: Alfred M. Walker

20100249074 - Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators: Sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.... Agent: Prout And Associates, LLC

20100249075 - Substituted tetralins as selective estrogen receptor-beta agonists: The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.... Agent: Eli Lilly & Company

20100249076 - Prodrugs of 9-aminomethyl tetracycline compounds: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249077 - Pyridylmethyl-sulfonamide compounds: e

20100249079 - Analogues of cilostazol: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that... Agent: Foley & Lardner LLP

20100249078 - Tetracyclic inhibitors of fatty acid amide hydrolase: Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as... Agent: Schwegman, Lundberg & Woessner, P.A.

20100249080 - Personal care composition: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a CB receptor activating agent, in which the CB receptor is preferably palmitoylethanolamide. A method of mitigating scalp itch.... Agent: Unilever Patent Group

20100249081 - Compositions and methods for treatment of renal disease: The invention relates to methods, compositions, and kits for the treatment of proteinuria and/or hypertension (e.g., proteinuria and/or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy... Agent: Casimir Jones, S.c.

20100249082 - Modulators of hypoxia inducible factor-1 and related uses: The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.... Agent: Clark & Elbing LLP

20100249083 - 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity: wherein dotted bonds represent optional double bonds; R6 is H, ═CH2, or —CH3, or —CH2—CH3; R7 is H, C1-4-alkyl, C2-5 alkenyl or C2-5-alkynyl, wherein the alkyl, alkenyl or alkynyl group may be substituted with 1 to 3 halogen atoms independently chosen from the group of fluorine or chlorine atoms; R11... Agent: Organon Usa, Inc. C/o Merck

20100249090 - Neurotherapeutic composition and method therefor: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are β-lactam compounds, particularly penam and cephem β-lactam antibiotics and non-antibiotic derivatives thereof.... Agent: Barnes & Thornburg LLP

20100249091 - Amide compounds useful in therapy: R6 represents C1-3 alkyl (optionally substituted by one or more substituents each independently selected from Rf), C3-5 cycloalkyl (optionally substituted by one or more halogen), CN or halogen; where Rf represents halogen or phenyl: and compositions, processes for the preparation, and uses thereof, e.g. in the treatment of endometriosis or... Agent: Pfizer Inc. Patent Department

20100249096 - Azetidines as mek inhibitors for the treatment of proliferative diseases: Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100249094 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100249092 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20100249093 - Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators: The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such... Agent: Kilyk & Bowersox, P.l.l.c.

20100249095 - Substituted spiro-amide compounds: e

20100249097 - Novel substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments: The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100249089 - Abcg2 inhibitor: e

20100249088 - Azolecarboxamide compound or salt thereof: [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100249086 - Compounds as cannabinoid receptor ligands: e

20100249087 - Compounds as cannabinoid receptor ligands:

20100249085 - Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100249084 - Substituted pyrimidines as adenosine receptor antagonists: Compounds of formula (I): wherein R1, R2 and R3 are as defined herein, including pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof.... Agent: Cooley LLP Attn: Patent Group

20100249098 - Oxypiperidine derivatives and methods of use thereof: The present invention relates to novel Oxypiperidine Derivatives, pharmaceutical compositions comprising the Oxypiperidine Derivatives and the use of the Oxypiperidine Derivatives for treating or preventing treating allergy, an allergy-induced airway response, congestion, hypotension, a cardiovascular disease, a gastrointestinal disorder, obesity, a sleep disorder, pain, diabetes, a diabetic complication, impaired glucose... Agent: Merck Patent Department (k-6-1, 1990)

20100249099 - Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy: Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.... Agent: Jones Day

20100249100 - Quinazolines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20100249101 - Malonamide derivatives with antithrombotic activity: The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100249102 - Heterotricyclic metalloprotease inhibitors: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and... Agent: Amgen Inc.

20100249103 - combination treatment: A combination of a levosimendan compound or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor shows synergistic effect in the prevention of stroke. Pharmaceutical compositions and medical kits comprising as a first active ingredient a levosimendan compound or a pharmaceutically... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100249104 - Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival: The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.... Agent: Sughrue Mion, PLLC

20100249105 - Indole and indoline derivatives and methods of use thereof: e

20100249106 - Methods of making and using therapeutically active thiophenepyrimidinone compounds: Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.... Agent: Crowell & Moring LLP Intellectual Property Group

20100249107 - Biomarkers for alzheimer's disease progression: This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms associated with the conversion from Mile Cognitive Impairment to dementia, e.g., Alzheimer's Disease (AD). The invention provides AD-associated mutations which are useful in the diagnosis, prognosis or therapeutic treatment... Agent: Novartis Institutes For Biomedical Research, Inc.

20100249108 - Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds: The present invention relates to substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted dipyrido-pyrimido-diazepine compounds, substituted benzo-pyrido-pyrimido-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249110 - Substituted pyrazolo-pyrimidine compounds: The present invention relates to substituted pyrazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted pyrazolo-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249109 - Substituted tetrahydropyrazolo-pyrido-azepine compounds: The present invention relates to substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249111 - Multi-ring compounds and uses thereof: Chemical agents, such as derivatives of hydroxy benzene moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of... Agent: Alan J. Grant Carella Byrne Bain Gilfillan

20100249112 - Combination of chk and parp inhibitors for the treatment of cancers: A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose)polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof is described.... Agent: Astrazeneca R&d Boston

20100249113 - Modulators of atp binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20100249114 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X, D, E, G, M, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100249115 - Substituted heterocyclic compounds: The present invention relates to substituted heterocyclic compounds and substituted tetrahydroisoquinoline compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzodiazepine compounds and substituted tetrahydroisoquinoline compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249116 - Compositions and methods for treating intoxications: Compositions and methods for treating intoxication by poisonous agents are described. In one aspect the pharmaceutical compositions include a phenothiazine compound, a dioic acid compound and a pharmaceutically acceptable carrier. In another aspect the pharmaceutical composition can include a phenothiazine compound, a nitroester compound, ethanol and a pharmaceutically acceptable carrier.... Agent: Steptoe & Johnson LLP

20100249117 - Factor xa inhibitors: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number... Agent: Portola Pharmaceuticals, Inc. C/o Swiss Tanner, P.C.

20100249118 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Foley & Lardner LLP

20100249119 - Heterocyclic compound and use thereof: m

20100249120 - Substituted pyrazolo-pyrrolo-pyridine-dione compounds: The present invention relates to substituted pyrazolo-pyrrolo-pyridine-dione compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted pyrazolo-pyrrolo-pyridine-dione compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249121 - Use of tetramic acid derivatives for controlling virus-transferring vectors: The present invention relates to the use of tetramic acid derivatives on their own and also of active compound combinations comprising, firstly, known tetramic acid derivatives and, secondly, further known insecticidal active compounds for controlling viroses transferred by insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100249124 - 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds: wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100249122 - Kinase inhibitors for preventing or treating pathogen infection and method of use thereof: The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat... Agent: Mckeon Meunier Carlin & Curfman LLC

20100249123 - Novel benzamide derivatives as modulators of the follicle stimulating hormone: The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1n are defined as in formula I; invention compounds are modulators of follicle-stimulating hormone—(“FSH”) which are useful for male and female contraception as well as other disorders modulated by... Agent: Edwards Angell Palmer & Dodge LLP

20100249125 - Inhibition of prostglandin e2 receptors for the treatment of endometriosis: The present invention describes the selective inhibition of prostaglandin receptors (PGE2), e.g., EP2 and EP4, by one or more inhibitors are selected from 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid and (4Z)-7-[(rel-1S,2S,5R)-5-((1,1′-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid and salts thereof as a potential therapeutic tool or to expand the spectrum of currently available treatment options for endometriosis and other... Agent: Chalker Flores, LLP

20100249126 - Pyrimidine derivatives used as pi-3-kinase inhibitors: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one... Agent: Novartis Institutes For Biomedical Research, Inc.

20100249127 - Substituted indolo-pyridinone compounds: The present invention relates to substituted indolo-pyridinone compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted indolo-pyridinone compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249128 - Novel 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and... Agent: Pfizer Inc

20100249129 - Compounds as cannabinoid receptor ligands: e

20100249133 - Apoptosis promoters: Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.... Agent: Jones Day

20100249130 - Biaryl compositions and methods for modulating a kinase cascade: The invention relates to compounds of formula IB and methods for modulating one or more components of a kinase cascade using these compounds.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249132 - Imidazole derivatives: Compounds of the formula (I), in which R1, D, E, L, Q, X and q have the meanings indicated in Claim 1, can and be employed for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100249131 - Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k: A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.... Agent: Astrazeneca R&d Boston

20100249134 - Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina: Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed.... Agent: Alcon

20100249135 - Sulfonamides and their use as a medicament: The present invention relates to the use of a sulfonamide compound of formula (I): wherein R1 is selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxy, methoxy, ethoxy, morpholino, R2 is selected from H, phenyl, substituted phenyl, CN, —SO2R, wherein R is phenyl or morpholino, —NC(O)Me,... Agent: Ratnerprestia

20100249136 - Organic compounds: The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of Parkinson's Disease and associated disorders... Agent: Novartis Corporate Intellectual Property

20100249137 - Novel seh inhibitors and their use: The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100249138 - Mpzp: a small molecule corticotropin-releasing factor type 1 receptor (crf1) antogonist: wherein W, X, Y and Z, R1 and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF1 system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior.... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20100249139 - 1,1,1-trifluoro-2-hydroxypropyl compounds: e

20100249141 - Novel inhibitors of folic acid-dependent enzymes: wherein R1=—NH2 or —OH, and C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.... Agent: Wolf Greenfield & Sacks, P.C.

20100249140 - Solid state forms of sitagliptin salts: Solid state forms of Sitagliptin salts, processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided.... Agent: Merchant & Gould PC

20100249142 - Imidazol[1,2-alpha]quinoxalines and derivatives for the treatment of cancers: l

20100249143 - Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds: wherein R1 is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a... Agent: Volpe And Koenig, P.C.

20100249144 - Substituted piperazines as cb1 antagonists: Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.... Agent: Merck Patent Department (k-6-1, 1990)

20100249145 - Inhibitors of vegf receptor and hgf receptor signaling: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100249146 - Heteroaryloxy quinazoline derivative: e

20100249148 - Novel pyrimidine compounds having benzyl (heterocyclic methyl) amine structure and medicament comprising the same: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group,... Agent: Greenblum & Bernstein, P.L.C

20100249147 - Sulfonyl-substituted 6-membered ring derivative: c

20100249149 - Inhibitors of protein kinases: are useful as inhibitors of cyclin dependent kinases such as CDK9.... Agent: Olson & Cepuritis, Ltd.

20100249150 - Stable pharmaceutical composition of freeze-dried tetrodoxin powder: This invention relates to a stable pharmaceutical composition of freeze-dried tetrodotoxin powder which contains trace amount of tetrodotoxin, substances which can stabilizes tetrodotoxin, including disaccharide(s) or polyglucose(s) or analogues thereof and solvent(s), and solvents which can help tetrodotoxin dissolve.... Agent: Fish & Richardson PC

20100249151 - Imidazo 1, 2-a pyrimidine derivatives for the treatment of diseases such as diabetes: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20100249152 - New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof: The present invention relates to a compound 4-substituted derivative of pyrazolo[3,4-d]pyrimidine or of pyrrolo[2,3-d]pyrimidine having the formula (I) and uses thereof, in particular for the treatment of bone related diseases and tumours.... Agent: Lucas & Mercanti, LLP

20100249153 - Substituted indolo-piperidine compounds: The present invention relates to substituted indolo-piperidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted indolo-piperidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100249154 - Compositions useful for treating disorders related to trpa1: Compounds and compositions for treating disorders related to TRPA1 are described herein.... Agent: Lando & Anastasi, LLP

20100249155 - Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use: The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PI3K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.... Agent: Morrison & Foerster LLP

20100249156 - Antiviral topical formulations in the form of a bio-adhesive gel: The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and... Agent: Birch Stewart Kolasch & Birch

20100249157 - Lpa receptor antagonist: (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by... Agent: Sughrue-265550

20100249159 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.... Agent: Millen, White, Zelano & Branigan, P.C.

20100249160 - Cancer treatment method: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.... Agent: Glaxosmithkline Global Patents, C.2111f

20100249158 - Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100249161 - 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.... Agent: High Point Pharmaceuticals, LLC

20100249162 - Process for the introduction of hydroxyethoxy side chain in bosentan: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100249163 - Renin inhibitors: e

20100249164 - Modulation of sleep with nr2b receptor antagonists: An NR2B receptor antagonist is useful, alone or in combination with other agents, for promoting wakefulness, treating narcolepsy, excessive daytime sleepiness, enhancing cognition, treating sleepiness associated with Alzheimer's disease, Parkinson's disease, fibromyalgia, chronic pain, sleep disorders, autism and attention deficit hyperactivity disorder.... Agent: Merck

20100249166 - Differential evaporation potentiated disinfectant system: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.... Agent: Cr Miles P.C.

20100249165 - Pdz domain modulators: t

20100249167 - Alkylsulfonyl-2,3-dihydrospiro[indene-1,4'-piperidine] analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders: In one aspect, the invention relates to compounds which are useful as inhibitors of glycine type 1 transporter (GlyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with glycine type 1 transporter (GlyT1) activity using the compounds and compositions. This... Agent: Ballard Spahr LLP

20100249168 - Compounds and formulations suitable for radical scavenging: The present invention relates to compositions and methods of using free radical scavengers with reduced 1O2 generation. In certain embodiments, these compositions and methods of use relate to fullerene-derived ketolactams and fullerene-derived keto lactam derivatives, fullerene derivatives, and/or fullerenes. In yet other embodiments, the invention relates to cosmetic or dermatological... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100249169 - Formulations for parenteral delivery of compounds and uses thereof: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.... Agent: Progenics Pharmaceuticals, Inc. C/o Wolf, Greenfield & Sacks, P.C.

20100249170 - Intranasal compositions: e

20100249171 - Ellipticine compounds for treating obesity: In Formula I, R1 is H, C1-6 alkyl, or C1-6 alkyl-aryl. Each of R2 and R4 of Formula I are independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkoxy, —OR2a, —SR2a, —C(O)R2a, —C(O)OR2a, —C(O)NR2aR2b, —NR2aR2b, C1-6 alkyl-NR2aR2b, —N(R2a)C(O)R2b, —N(R2a)C(O)OR2b, —N(R2a)C(O)NR2aR2b, —OP(O)(OR2a)2, —S(O)2OR2a, —S(O)2NR2aR2b, —CN, —NO2, cycloalkyl,... Agent: Townsend And Townsend And Crew, LLP

20100249172 - 9-chloro noscapine and its use in treating cancers, including drug-resistant cancers: 9-Chloro-nos, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-chloro-nos, and methods of preparation and use thereof are disclosed. 9-Chloro-nos is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing... Agent: Intellectual Property / Technology Law

20100249174 - Ccr1 antagonists and methods of use therefor: C

20100249173 - Dihydroquinolinones as ectoparasiticides: Disclosed are uses of dihydroquinolinone derivatives for combating ectoparasites on non-human animals. Example ectoparasites include, for example, representatives of the order acarina, including ticks and mites. Also disclosed are compositions containing dihydroquinolinone derivatives.... Agent: Novartis Animal Health US Inc.

20100249177 - Compositions and methods for treating middle-of-the-night insomnia: The present invention provides compositions for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100249178 - Compositions and methods for treating middle-of-the-night insomnia: The present invention provides compositions having a therapeutically effective amount of zolpidem, carbonate buffer, bicarbonate buffer, and a mixture comprising large and fine particles of silicon dioxide. Compositions having a therapeutically effective amount of zolpidem, carbonate buffer, bicarbonate buffer, and sodium stearyl fumarate are also described.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100249175 - Dicationic compounds which selectively recognize g-quadruplex dna: Dicationic compounds that are highly selective for binding G-quadruplex DNA are described. Several compounds exhibit groove binding toward G-quadruplex DNA and in vitro and in vivo activity versus Trypanosoma brucei rhodesiense. The compounds represent novel drugs for the treatment of cancer, malaria, leishmania, and trypanosomiasis.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100249176 - Heterocycle amide t-type calcium channel antagonists: The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck

20100249179 - Farnesoid x receptor agonists: The present invention provides novel isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.... Agent: Glaxosmithkline Global Patents, C.2111f

20100249180 - Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20100249181 - Hiv protease inhibiting compounds: e

20100249182 - Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same:

20100249183 - Therapeutic use of n-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives: The invention concerns therapeutic use of compounds of general formula (I), wherein n, the pyrrolopyridine ring, X1, Z1, Z2, Z3, Z4, Z5 and W are as defined herein.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100249184 - Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction: The present invention relates to a method of inducing cancer cells into dormancy and treating cancer in a subject. This method involves administering to a subject an effective amount of a compound that disrupts interaction between urokinase plasminogen activator receptor and integrin, thereby including cancer cells into dormancy and treating... Agent: Nixon Peabody LLP - Patent Group

20100249185 - Method for inhibiting topoisomerase ii: The present invention relates to compounds that inhibit the activity of Hsp90 and inhibit topoisomerase II.... Agent: Foley & Lardner LLP

20100249186 - Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists: wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing... Agent: Theravance, Inc.

20100249187 - Novel dicarboxylic acid derivatives as s1p1 receptor agonists: The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and... Agent: Stites & Harbison PLLC

20100249189 - Nitric oxide donor compounds: e

20100249188 - Prediction of qt prolongation based on snp genotype: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.... Agent: Hoffman Warnick LLC

20100249190 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV... Agent: Louis J. Wille Bristol-myers Squibb Company

20100249191 - N-methyl benzamide derivatives: wherein A represents C or N; R represents haloalkyl; X represents halogen or haloalkyl; l represents 0, 1 or 2; Y represents halogen, alkyl, alkoxy, haloalkyl, cyano, nitro, amino, acylamino, alkoxycarbonylamino, haloalkoxycarbonyl-amino or alkylsulfonylamino; m represents 0, 1 or 2; and G represents any one selected from heterocyclic groups described... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100249192 - Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: e

20100249194 - 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof: wherein: R1 is hydrogen, cyano, halogen, R8, formyl, —C(O)R8, —C(O)OR8, —C(O)NR9R10, or —C(S)NH2; R2 is R8 or —S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, —C(O)R12, —S(O)nR12 or... Agent: Judy Jarecki-black Ph.d., J.d.

20100249193 - Nematicidal, insecticidal and acaricidal active ingredient combinations comprising pyridyl-ethylbenzamides and insecticides: The present invention relates to novel active ingredient combinations which consist of fluopyram and further known active insecticidal ingredients, and are very suitable for controlling animal pests, such as insects and/or unwanted acarids and/or nematodes, in foliar and soil application and/or in seed treatment.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100249195 - Pyridylphenyl compounds for inflammation and immune-related uses: e

20100249196 - Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten 2-amine: Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or... Agent: Pepper Hamilton LLP

20100249197 - Carbamic acid compounds comprising an amide linkage as hdac inhibitors: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)— and —C(═O)NR1—;... Agent: Nixon & Vanderhye, PC

20100249198 - (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them: The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the... Agent: King & Spalding

20100249199 - Hard surface treatment compositions with improved mold or fungi remediation properties: Provided are hard surface treatment compositions which provide improved mold and/or fungi remediation properties which compositions are formed from two aqueous mixtures which are admixed immediately prior to use or upon use. The hard surface treatment compositions contain an oxidizing agent, preferably a hypochlorite. In addition to a mold and/or... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100249200 - Novel compounds 569: o

20100249201 - 3-3-di-substituted-oxindoles as inhibitors of translation initiation: Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.... Agent: Banner & Witcoff, Ltd.

20100249202 - Agent for fungal dermatitis: The invention relates to a therapeutic agent for fungal dermatitis, containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, and a composition for the treatment of fungal dermatitis, containing luliconazole or lanoconazole in a substantially dissolved state as an active ingredient.... Agent: Leydig Voit & Mayer, Ltd

20100249203 - Compounds that inhibit trpv1 and uses thereof: e

20100249204 - Calcium salts of indole derived statins: wherein R1 is alkyl, cycloalkyl or aralkyl; R2, R3 and R4 are independently hydrogen, halogen or alkyl; R5 and R6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an... Agent: Novartis Corporate Intellectual Property

20100249205 - Metabolites of wortmannin analogs and methods of using same: Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100249206 - Modified lysine-mimetic compounds: Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed.... Agent: Wyeth LLC/finnegan Henderson, LLP

20100249207 - Synthesis of pyrrolidine compounds: Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.... Agent: Wyeth LLC/finnegan Henderson, LLP

20100249222 - Methods of treating skin with aromatic skin-active ingredients: A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting... Agent: Fulbright & Jaworski L.L.P.

20100249223 - New use for cannabinoid-containing plant extracts: The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA... Agent: Wolf Greenfield & Sacks, P.C.

20100249224 - Methods and compositions for modulating glutamate dehydrogenase: Compositions, compounds, and methods for modulating the activity of glutamate dehydrogenase are disclosed. In addition, compositions, compounds, and methods for regulating insulin secretion and treating hyperinsulism/hyperammonemia and/or diabetes are disclosed.... Agent: Bryan Cave LLP

20100249225 - C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders: Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.... Agent: Crowell & Moring LLP Intellectual Property Group

20100249226 - Tumor selective and biodegradable cyclotriphosphazene-platinum(ii) conjugate anticancer agent, and preparation method thereof: Disclosed are a novel cyclotriphosphazene-platinum(II) complex conjugate anticancer agent, showing high selectivity to tumor tissues due to the enhanced permeability and retention effect in tumor tissues and a preparation method thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20100249227 - Compositions containing zinc salts for coating medical articles: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.... Agent: Baker Botts L.L.P.

20100249228 - Sarms and method of use thereof: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.... Agent: Pearl Cohen Zedek Latzer, LLP

20100249229 - Bicyclic gamma-amino acid derivative: i

20100249230 - Antiviral activity of cyclopentene nitro-ester and derivatives: Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol,... Agent: Smith Hopen, Pa

20100249231 - Hsp90 inhibitors of protein-protein interaction hsp90 chaperone complexes and therapeutic uses thereof: A novel Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding and methods for treating diseases such as pancreatic cancer are disclosed.... Agent: Macmillan Sobanski & Todd, LLC

20100249232 - Mosquito repellent: The present invention relates to a mosquito repellent comprises at least one or more selected from the group consisting of neric acid and derivatives thereof in an effective amount to repel mosquito.... Agent: Shutts & Bowen, LLP

20100249233 - Compound and use thereof in the treatment of amyloidosis: e

20100249236 - Adhesive and plaster: An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms... Agent: The Nath Law Group

20100249235 - Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome: The invention provides methods and compositions for stimulating weight loss or lowering triglyceride levels in an individual in need thereof. In methods of the invention, a pharmaceutical composition comprising a therapeutically effective amount of DITPA, and optionally one or a plurality of lipid lowering agents, is administered to an individual... Agent: Klarquist Sparkman, LLP

20100249234 - Methods of reducing virulence in bacteria: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a phenylpropanoid-type inhibitory compound.... Agent: Michael Best & Friedrich LLP

20100249237 - Non-steroidal anti-inflammatory drug dosing regimen: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.... Agent: Philip S. Johnson Johnson & Johnson

20100249238 - Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation: The present patent application refers to pharmaceutical compositions comprising at least a semicarbazone or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof, for the treatment of inflammatory, febrile and painful inflammatory conditions, inflammatory edema and peripheral or central neurophatic painful conditions or prevention of signs and symptoms... Agent: Nixon & Vanderhye, PC

20100249239 - Bis(thio-hydrazide amide) formulation: e

20100249240 - Synergistic mixed poloxamer systems for the solubilisation of drugs: Drugs which are difficult to solubilise in water, and especially those which otherwise cause pain on injection, can be readily formulated and typically administered with substantially less pain when solubilised in synergistic, aqueous micellar preparations of poloxamers. Such preparations may also be prepared with less, or without, co-solvents.... Agent: Foley & Lardner LLP

20100249241 - N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same: Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific... Agent: Schwegman, Lundberg & Woessner, P.A.

20100249242 - Method of reducing neuronal cell damage: The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the... Agent: Fennemore Craig

20100249243 - Novel beta-hydroxyketones and beta-alkoxyketones with estrogenic activity: This invention relates to β-hydroxyketones and β-alkoxyketones of formula (I), to their use as estrogen receptor modulators, and to methods for their preparation.... Agent: Birch Stewart Kolasch & Birch

20100249244 - Methods and compositions for treating dermatological diseases and conditions: The presently claimed and disclosed inventive concept(s) contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These... Agent: Dunlap Codding, P.C.

20100249245 - Sterilizing composition: Disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant having a cloud point in the range of about 30° C. to 50° C. Also disclosed is... Agent: Pryor Cashman, LLP

20100249246 - Therapeutic compounds: A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100249247 - Antimicrobial compositions: An antimicrobial composition for use as a disinfectant or a preservative. The disinfectant may be used in disinfecting and cleaning surfaces. The preservative is particularly useful in personal care and cosmetic products, and pharmaceuticals. The composition includes a base component and an alkyl mono propylene glycol ether, an alkyl mono... Agent: Joel D. Skinner, Jr. Skinner And Associates

20100249248 - Ligand agents for peroxisome proliferator-activated receptors (ppars):

20100249249 - Reduction of the formation of biofilm by means of multifunctional copolymers: Multifunctional copolymers, washing and cleaning agents comprising said copolymers, and use of those copolymers for reduction of the attachment of microorganisms and/or for reduction of the formation of biofilm on surfaces.... Agent: Henkel Corporation

20100249250 - Reversible biogel for manipulation and separation of single-walled carbon nanotubes: The invention provides the use of novel, binary guanosine gels for simple, rapid and nondestructive solubilization of individual single walled carbon nanotubes (SWNTs) at high concentrations. The gels exhibit selectivity between metallic and semiconducting SWNTs and, further, among SWNTs with different chiralities.... Agent: Wolf Greenfield & Sacks, P.C.

  
09/23/2010 > patent applications in patent subcategories. class, title,number

20100240574 - Heyl as a therapeutic target and a diagnostic marker for neoplasia and uses therefor: The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention... Agent: Edwards Angell Palmer & Dodge LLP

20100240575 - Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same: Disclosed is an immunogenic hybrid polypeptide comprising a mimetic peptide of a B cell epitope of apolipoprotein B-100 and helper T cell epitope, the mimetic peptide being fused at its C-terminus to an N-terminus of the helper T cell epitope. Also disclosed is a vaccine composition for preventing or treating... Agent: Kenneth L Kohn Kohn & Associates

20100240576 - Anticonvulsant combination therapy: The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.... Agent: Harness, Dickey, & Pierce, P.l.c

20100240577 - Bacteriocins and novel bacterial strains: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.... Agent: Usda, Ars, Ott

20100240578 - Anti-h5n1 influenza activity of the antiviral protein cyanovirin: The invention is directed to a method of inhibiting prophylactically or therapeutically an H5N1 viral infection in a host, which method comprises administering to the host an anti-viral effective amount of an antiviral protein comprising the amino acid sequence of SEQ ID NO: 1 or a nucleic acid encoding the... Agent: Leydig, Voit & Mayer, Ltd.

20100240579 - Detection of cell surface binding molecules using a phage display blocking assay: The present invention relates to the use of a phage blocking assay to determine unknown binding molecule present on or in the surface of a cell, a non-infectious moiety, a bacteria, a virus, or another pathogen. In particular embodiments, the invention relates to the identification of unknown receptors on a... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100240580 - Azoloarine derivatives, method for the production thereof, pharmaceuticals containing these compounds and the use thereof: e

20100240581 - Selective proteasome inhibitors for treating diabetes: Methods of modulating chronic low-grade inflammation are provided. More particularly, methods of treating diabetes, such as for example, type-2 diabetes mellitus, in a mammal by administering an effective amount of a selective proteasome inhibitor are provided. Also provided are unit dosage forms of such inhibitors.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100240582 - Peptides and related molecules that modulate nerve growth factor activity: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are... Agent: Amgen Inc.

20100240588 - Compound for use in the treatment of peripheral neuropathies: e

20100240589 - Diastereomeric peptides useful as inhibitors of membrane protein assembly: The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically... Agent: Fennemore Craig

20100240585 - In vivo cell surface engineering: The present invention provides methods and compositions for the in vivo engineering of cell surfaces, such as tumor cell surfaces, with one or more immune co-stimulatory polypeptides. The methods, compositions and engineered cells are useful, for example, to stimulate an immune response against the cells. When the engineered cell surfaces... Agent: Foley And Lardner LLP Suite 500

20100240584 - Nematode-extracted serine protease inhibitors and anticoagulant proteins: Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized... Agent: Fulbright & Jaworski L.L.P.

20100240586 - Peg modified exendin or exendin analog and compositions and use thereof: Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of formulas I-IV. Compositions including the PEG derivative modified... Agent: Perkins Coie LLP

20100240590 - Peptides and related molecules that bind to tall-1: wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain,... Agent: Perkins Coie LLP

20100240583 - Soluble protein and utilization of the same: A compound or a salt thereof inhibiting activity or expression of the protein of the present invention, a neutralizing antibody against the protein, a polynucleotide that are complementary to a polynucleotide coding the protein, and the like can be used as an agent for preventing and/or treating neurodegenerative diseases and... Agent: Sughrue-265550

20100240587 - Stable formulations of amylin and its analogues: The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100240591 - Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection: TPP II (tripeptidyl peptidase II) inhibitors are useful in the treatment of autoimmune and/or inflammatory diseases, for example Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Sjögrens Syndrome, Diabetes Mellitus Type I or II, Psoriasis, Eczema, Ulcerous Colitis, and Chron's Disease, or transplant rejection. Suitable compounds comprise tripeptide compounds of general... Agent: Brooks Kushman P.C.

20100240592 - Template-fixed peptidomimetics with antimicrobial activity: Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100240593 - Strontium-apatite cement preparation cements formed therefrom, and use thereof: Calcium-strontium-hydroxyphosphate (strontium-apatite-) cement preparations are described, comprising a powder mixture, which contains molar quantities of the components calcium (Ca), strontium (Sr) and phosphate (P) in the mixture in the ranges 1.00<Ca/P≦1.50 and 0<Sr/P<1.5, together with an alkali salt or an ammonium salt of phosphoric acid, and with water and/or an... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100240594 - Targeted delivery of chemotherapeutic agents: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents.... Agent: Dla Piper LLP (us)

20100240595 - Improved antitumoral treatments: The present invention relates to combinations of Aplidine with Gemcitabine, and the use of these combinations in the treatment of cancer.... Agent: King & Spalding

20100240596 - Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac: The present invention provides compositions and methods for use in treatment of premature rupture of membrane. The compositions of the invention include a therapeutic amount of an avian thick egg white composition. Preferably, the compositions include the purified thick egg white protein, ovomucin. The methods of the invention involve injecting... Agent: Fulbright & Jaworski L.L.P.

20100240597 - Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same: A method of preparing molecules of interest for delivery to eukaryotic cells is shown, wherein a ricin B chain subunit not having a ribosome inactivating subunit and retaining lectin activity is modified by modifying the first cysteine residue to be absent or substituted with an amino acid other than cysteine,... Agent: Joe D. Calhoun

20100240598 - Peptides and peptide mimetics to inhibit the onset and/or progression of fibrotic and/or pre-fibrotic pathologies: This invention provides methods of inhibiting the onset or progression of a fibrotic disease (or pre-fibrotic pathology) in a mammal. The method involves administering oen or more peptides (e.g., class A amphipathic helical peptides, G* peptides, etc.) as described herein to a mammal in need thereof, in an amount effective... Agent: Weaver Austin Villeneuve & Sampson LLP

20100240599 - Antioxidant constituents: An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100240600 - Anti-norovirus agent and composition containing the same: Provided is an anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus. The anti-norovirus agent includes, as an active ingredient, an extract from a plant... Agent: The Webb Law Firm, P.C.

20100240601 - Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is... Agent: Brinks Hofer Gilson & Lione

20100240602 - Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds: The present invention provides methods and formulations for optimizing the anti-cancer and anti-HIV activities of a camptothecin drug, including camptothecin and its related analogs including 9-aminocamptothecin and 9-nitrocamptothecin. The invention involves methodologies and formulations that limit human serum albumin-mediated reduction of the anti-cancer and anti-HIV effects of the camptothecins, and... Agent: Stites & Harbison PLLC

20100240603 - Expression inhibitor of nuclear transcription factor ap-1 and pharmaceuticals and products using the same: An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present invention is characterized by containing chamaemeloside. In the present invention, chamaemeloside may be contained as... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100240732 - Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function: Compositions for countering immune attenuating/suppressive pathways comprise targeting agents or aptamer targeted RNAi-mediated gene silencing (siRNA/shRNA). These compositions have broad applicability in the treatment of many diseases.... Agent: Novak Druce + Quigg LLP (wpb)

20100240733 - Histone demethylation mediated by the nuclear amine oxidase homolog lsd1: LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4... Agent: Foley Hoag, LLP (w/huv Hmv) Patent Group

20100240731 - Lipopeptides for delivery of nucleic acids: Lipopeptide compounds comprising a peptide having 2 to 100 amino acid residues, and having a lipophilic group attached to at least one terminus of the peptide or to at least one amino acid residue of the peptide, and salts and uses thereof. The lipophilic group may be attached to the... Agent: Eckman Basu LLP

20100240734 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100240730 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, cosmetic, cosmeceutical, prophylactic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA),... Agent: Merck C/o Sirna Therapeutics, Inc.

20100240738 - Antisense modulation of kinesin-like 1 expression: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like... Agent: Knobbe, Martens, Olson & Bear, LLP

20100240737 - Enzyme-prodrug therapy for prosthetic joint repair: The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides adenoviral vectors and prodrugs for simultaneous, separate or sequential use in the destruction of interface tissue allowing... Agent: Cozen O'connor, P.C.

20100240740 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Morris Manning Martin LLP

20100240736 - Novel compounds for the treatment or alleviation of edema, and methods for their use: Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology.... Agent: Dla Piper LLP (us)

20100240735 - Pharmaceutical compositions for angiogenic therapy: The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of... Agent: Townsend And Townsend And Crew, LLP

20100240741 - Pharmaceutical compositions for the administration of aptamers: Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.... Agent: Townsend And Townsend And Crew, LLP

20100240739 - Widespread gene delivery to motor neurons using peripheral injection of aav vectors: The present invention relates to compositions and methods, in particular to methods based on systemic injection of rAAV, for delivering genes to cells of the central nervous system in mammals, such as brain neurons or glial cells, and in particular to motor neurons or glial cells of the spinal cord... Agent: Nixon & Vanderhye, PC

20100240604 - Protected nucleotide analogs: Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates.... Agent: Knobbe Martens Olson & Bear LLP

20100240605 - Novel immunotherapy strategy: The present invention relates to polyacetal-carboxylic acids, more in particular chlorite-oxidized oxyamylose (COAM) for use as a medicine, more in particular for the treatment or prevention of cancer and auto-immune disorders or relates to the use of polyacetal-carboxylic acids for the manufacture of a medicament for the prevention or treatment... Agent: Clark & Elbing LLP

20100240606 - Associations of xanthogenates and cyclodextrins, and their use: whereby R1 represents a possibly substituted aryl or alkyl residue and R2 represents a metal atom, a possibly substituted alkyl, alkoxy, amino or ammonium group or halogen, and a cyclodextrin, whereby the cyclodextrin can be either a substituted or non-substituted alpha-, beta- or gamma-cyclodextrin. Furthermore, the invention is related to... Agent: Fanelli Strain & Haag PLLC

20100240607 - Dextrin-containing composition for preventing surgical adhesions: A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.... Agent: Carella, Byrne, Cecchi, Olstein, Brody & Agnello

20100240608 - particle stabilised oil-in-water emulsion: Thus an oil-in-water emulsion comprising 0.001-50%, preferably 0.001-30%, more preferably 0.001-10% w/w oil and 0.001 to less than 0.5%, preferably 0.001-0.4%, more preferably 0.01-0.4% w/w a gelled particle emulsifier, wherein the gelled particle emulsifier comprises at least one gellable polysaccharide, wherein the gelled particle emulsifier has a largest dimension of... Agent: Unilever Patent Group

20100240609 - Phthalocyanine salt formulations: Pharmaceutical compositions of phthalocyanine compounds with a structure according to Formula (I) are described. Phthalocyanines are photosensitizer compounds having a phthalocyanine ring system that can be used for photodynamic therapy. Different phthalocyanines and phthalocyanine salts are shown to have useful characteristics such as water solubility, oil solubility, or tunable photostability.... Agent: Calfee Halter & Griswold, LLP

20100240610 - Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof: This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one... Agent: Jones Day

20100240611 - Methods for preparing dpp-iv inhibitor compounds: Methods for preparing an inhibitor of dipeptidyl peptidase IV, as well as formulations of such inhibitors of dipeptidyl peptidase IV that have a high degree of stability including under warm, humid storage conditions.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100240612 - Prenylated bisphosphonates as anti-tuberculosis agents: The invention provides methods to treat a mycobacterium infection and methods to inhibit mycobacterial polyprenyl pyrophosphate synthesis with a compound of formula I. The invention also provides novel compounds of formula I as well as salts and prodrugs thereof.... Agent: Viksnins Harris & Padys Pllp

20100240613 - Pyrimidine compound and medical use thereof: wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor... Agent: Leydig Voit & Mayer, Ltd

20100240614 - Indole compounds bearing aryl or heteroaryl groups having sphingosine 1-phosphate (s1p) receptor biological activity: The invention provides well-defined aryl and/or heteroaryl substituted indoles that are useful as spingosine-1-phosphate agonists or antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20100240615 - Nitric oxide donors: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.... Agent: Merchant & Gould PC

20100240616 - Novel lipid compounds: Y is a C14-C22 alkenyl group with at least one double bond, having E and/or Z configuration; or any pharmaceutically acceptable complex, solvate, salt or pro-drug thereof, with the proviso that R1 and R2 are not simultaneously a hydrogen atom. Also disclosed are pharmaceutical compositions and lipid compositions comprising such... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100240617 - Bicyclic sphingosine 1-phosphate analogs: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Prout And Associates, LLC

20100240618 - Substituted piperazines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20100240619 - Fungicidal mixtures: m

20100240620 - 3-cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases: The present application relates to novel aryl-substituted 3-cyano-5-thiazolyl- and 3-cyano-5-thiadiazolyl-1,4-dihydropyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100240621 - Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid: The present invention relates to topical pharmaceutical compositions comprising fusidic acid and a corticosteroid. More particularly, the present invention relates to topical pharmaceutical compositions comprising fusidic acid and mometasone or halobetasol or their esters, processes for preparing the same, and the use of such compositions for prevention and treatment of... Agent: Glenmark Generics Inc.

20100240623 - 8-oxoadenine derivatives acting as modulators of tlr7: The present invention provides 8-oxoadenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as... Agent: Morgan Lewis & Bockius LLP

20100240626 - Antiemetic-oral contraceptive combination: The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic.... Agent: Merchant & Gould PC

20100240627 - Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors: Methods of treating a glucocorticoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering, in combination, a glucocorticoid receptor agonist and a PPAR agonist in therapeutically effective amounts. It is an aspect of the present invention that the amount of the glucocorticoid receptor... Agent: Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C.

20100240622 - Nitric oxide enhancing prostaglandin compounds, compositions and methods of use: The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating ophthalmic disorders; (b) treating cerebrovascular disorders;... Agent: Wilmerhale/nitromed

20100240625 - Ophthalmic formulations of cetirizine and methods of use: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100240624 - Ophthalmic formulations of ketotifen and methods of use: The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100240628 - Skin treatments: Compositions comprising an LXR activator and retinoic acid and/or a metabolic precursor thereto are useful in reducing the effects of chronoageing and/or photoageing of the skin.... Agent: Unilever Patent Group

20100240629 - Polymorphs of fluticasone furoate and processes for preparation thereof: The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furoate and at least one pharmaceutically acceptable excipient; and the use of the crystalline forms of Fluticasone furoate in the... Agent: Kenyon & Kenyon LLP

20100240630 - Compounds and therapeutic uses thereof: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myrexis, Inc. C/o Cpa Global

20100240631 - Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.... Agent: Abelman, Frayne & Schwab

20100240633 - Cancer treatment methods: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Harbor Biosciences, Inc.

20100240632 - Drug for improving hyperglycemia: A compound having a hyperglycemia improving effect and a hemoglobin A1c lowering action such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol is used as an active ingredient of a drug or food or drink for improving hyperglycemia.... Agent: Knobbe Martens Olson & Bear LLP

20100240634 - Fluorene compound and pharmaceutical use thereof: c

20100240635 - Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them: Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator and/or an NMDA receptor antagonist.... Agent: The Firm Of Hueschen And Sage

20100240636 - Pyrimidinyl-propionic acid derivatives and their use as ppar agonists: The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPARγ agonist, through activating PPAR-RXR heterodimers that intereacts with specific... Agent: Baker Botts LLP C/o Intellectual Property Department

20100240637 - Inhibitors of the interaction between mdm2 and p53: e

20100240640 - (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists: wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers... Agent: Fish & Richardson P.C.

20100240638 - Organic compounds and their uses: The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100240639 - Sulfonyl-derivatives as novel or histone deacetylase: e

20100240641 - Aldosterone synthase and/or 11b-hydroxylase inhibitors:

20100240642 - 1h-indole-2-carboxylic acid derivatives useful as ppar modulators: The present invention relates to certain indole derivatives that are modulators of PPARγ, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.... Agent: Glaxosmithkline Global Patents, C.2111f

20100240643 - Use of active substance combinations having insecticidal properties for controlling animal pests from the stink bug family: The present invention relates to the use of active substance combinations which consist firstly of known cyclic ketoenols and secondly of further known insecticidal active substances, for controlling animal pests from the stink bug family (Pentatomidae).... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100240644 - Morpholine derivative: e

20100240645 - Combination of checkponit kinase (chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer: A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and an ataxia telangiectasia mutated (ATM) inhibitor, or a pharmaceutically acceptable salt thereof is described.... Agent: Astrazeneca R&d Boston

20100240646 - Pyrrolo-triazine aniline compounds useful as kinase inhibitors: c

20100240648 - Hexahydro-pyrrolo-isoquinoline compounds: Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100240647 - Treatment of alzheimer's disease and related conditions: Compounds of formula (I) inhibit microtubule affinity regulating kinase (MARK), and hence are suitable for treating diseases associated with abnormal phosphorylation of tau.... Agent: Merck

20100240649 - Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors: m

20100240650 - Substituted pyrrolines as kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20100240651 - Water-soluble thalidomide derivatives: wherein R1 represents H, or a C1-4 alkyl group; R2 represents H, a C1-4 alkyl group, C(O)CHR4NR5R6, or C(O)W; or R1 and R2 taken together represent 1,3-propylene; R3 represents H, a C1-4 alkyl group, C(O)CHR4NR5R6, or C(O)W; or R2 and R3 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, CH2OCH2, CH2SCH2... Agent: Matthias Scholl

20100240653 - Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto: The present invention relates to certain biphenyl sulfonamide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3-receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as, cognitive disorders, epilepsy,... Agent: Fish & Richardson P.C.

20100240654 - Hydrazide derivatives: e

20100240652 - Pyridine derivatives as sodium channel modulators: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.... Agent: Pfizer Inc. Patent Department

20100240655 - Bromo-phenyl substituted thiazolyl dihydropyrimidines: Bromo-phenyl substituted thiazolyl dihydropyrimidines and combinations thereof with other antiviral agents for combating HBV infections.... Agent: Jones Day

20100240656 - Compounds as hsp90 inhibitors: The invention provides novel compounds of formula (I) wherein: one of the a, b, c or d members is a nitrogen atom and the remaining members are carbon atoms; and R3 is a radical selected from the group consisting of: —S—R14 and —CH2—R15. The compounds of formula (I) are useful... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100240657 - Chemical compounds: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100240658 - Oxadiazole derivatives: e

20100240659 - Nitrogen-containing heterocyclic derivative having 11ss-hydroxysteroid dehydrogenase type i inhibitory activity:

20100240660 - New histone deacetylases inhibitors: where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of... Agent: Mccormick, Paulding & Huber LLP

20100240661 - Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors: e

20100240662 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic... Agent: Seed Intellectual Property Law Group PLLC

20100240663 - Heterocycles as potassium channel modulators: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia,... Agent: Townsend And Townsend And Crew, LLP

20100240664 - Solubilized topoisomerase poison agents: A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic... Agent: Viksnins Harris & Padys Pllp

20100240665 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell expresses certain sensitivity or resistance... Agent: Scully Scott Murphy & Presser, PC

20100240667 - Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride: Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations.... Agent: Millen, White, Zelano & Branigan, P.C.

20100240666 - Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases: y

20100240668 - Myosin light chain kinase inhibitor compounds, compositions and related methods of use: Pyridazinyl compounds, compositions and related methods of use.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20100240669 - New compounds: wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100240670 - 4-[(arylmethyl)aminomethyl]piperidine derivatives, their preparation and their therapeutic application: e

20100240671 - Substituted heterocyclic compounds: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases... Agent: Feng Shao Pepper Hamilton LLP

20100240673 - Eml4-alk fusion gene: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion... Agent: Sughrue Mion, PLLC

20100240672 - Melt-processed imatinib dosage form: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be... Agent: Edwards Angell Palmer & Dodge LLP

20100240674 - Use of compounds derived from benzamidine methanesulphonate or a pharmaceutically acceptable salt thereof, for example imatinib mesylate, for the preparation o f a drug for the treatment of neurodegenerative niemann-pick c disease (npc): This invention relates to the use of imatinib mesylate for the treatment of metabolism disorders characterized by neurodegeneration, in particular a metabolism disorder characterized by an inability to metabolize lipids such as in persons with Niemann-Pick Type C disease. More specifically, this invention relates to a method of treating neurodegenerative... Agent: Merchant & Gould PC

20100240675 - Therapeutic agents useful for treating pain: where X is S or O and Ar2, R1, R2, R3, R8, n, m, t, and v are disclosed herein, or a pharmaceutically acceptable salt thereof (a “3-substituted Pyridyl Compound”), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an... Agent: Dechert LLP

20100240676 - Thiazole derivatives: Compounds of the formula (I), in which R1, R2, R3, R4, K, G, E and W... Agent: Millen, White, Zelano & Branigan, P.C.

20100240677 - Compounds as pde iv and tnf inhibitors: Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100240679 - 4-phenylpiperidine derivatives as renin inhibitors: exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as... Agent: Novartis Institutes For Biomedical Research, Inc.

20100240678 - Leukotriene b4 inhibitors: h

20100240680 - Purine derivatives as a2a agonists: Compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein W, R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds... Agent: Novartis Corporate Intellectual Property

20100240681 - Valomaciclovir polymorphs: The present invention relates to crystalline forms of valomaciclovir, processes for preparing crystalline forms of valomaciclovir, pharmaceutical compositions thereof and methods of using thereof.... Agent: Ecotech Law Group, P.C.

20100240682 - Phophylactic or therapeutic agent for inflamatory disease comprising thymidine phosphorylase inhibitor as active ingredient: e

20100240683 - Combination therapy, composition and methods for the treatment of cardiovascular disorders: The present invention relates to a combination therapy for the treatment of cardiovascular disorders. More particularly, the invention relates to compositions combining long-chain optionally substituted amphipatic carboxylates (known as MEDICA drugs) and particularly, M16αα, M16ββ and M18γγ, with HMG-CoA reductase inhibitors (known as statins). The compositions of the invention may... Agent: Buchanan, Ingersoll & Rooney PC

20100240684 - Minoxidil aqueous composition containing bile acid: An object of the present invention is to provide a liquid composition wherein minoxidil can be dissolved at a relatively high concentration (the saturating amount or above), stimulation of skin and stickiness is suppressed without containing an organic solvent, and excellent effects of percutaneous absorption is achieved. The present invention... Agent: Sughrue Mion, PLLC

20100240685 - 2-s-benzyl substituted pyrimidines as crth2 antagonists: Provided herein are 2-S-benzyl pyrimidine compounds having CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity, useful for the prophylaxis and treatment of diseases associated with CRTH2 activity, including the treatment of allergic diseases, eosinophil-related diseases and basophil-related diseases.... Agent: Jones Day

20100240686 - Chemical compounds: o

20100240687 - Method for checking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism: The method for qualitative and quantitative detecting of the extend of use and the correct process flow of the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and the structural and/or functional parameter... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20100240688 - 1,3-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1 h-1,4 bipyridinyl-2-ones: wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype... Agent: Gardner Groff Greenwald & Villanueva. PC

20100240689 - N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptable salts thereof. The aryl group can be a phenyl ring or a five- or six-membered heterocyclic ring (heteroaryl).... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100240690 - Compositions containing opioid antagonists: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having... Agent: Feldman Gale, P.A.

20100240691 - Morphinan derivatives with high oral bioavailability: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.... Agent: Elmore Patent Law Group, PC

20100240692 - [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition... Agent: Intellectual Property / Technology Law

20100240693 - oxime and hydroxylamine substituted thiazolo [4,5-c] ring compounds and methods: Thiazolo[4,5-c]ring compounds, (e.g. thiazolopyridine, thiazoloquinoline, 6,7,8,9-tetrahydrothiazoloquinoline, thiazolonaphthyridine, and 6,7,8,9-tetrahydrothiazolonaphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases... Agent: Wolf Greenfield & Sacks, P.C.

20100240694 - Salt of naphthyridine carboxylic acid derivative: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

20100240695 - Stabilized zolpidem pharmaceutical compositions: Pharmaceutical compositions for buccal delivery of zolpidem comprising an effective amount of zolpidem and a carbonate and bicarbonate buffer system in an amount sufficient to raise the pH of saliva to at least 8.5, and wherein the carbonate forms a coating on the bicarbonate wherein the amount of carbonate coating... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100240696 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100240697 - Pharmaceutical composition for treating overactive bladder: e

20100240698 - Macrocyclic inhibitors of hepatitis c virus:

20100240699 - Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists: Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist lacking significant alpha-2A receptor activity.... Agent: Allergan, Inc.

20100240700 - Prophylactic pretreatment with antioxidants: Methods, compositions, and uses for pre-treating patients who are susceptible to ischemia, including stroke, with nitroxides, in order to prevent or ameliorate the effects of stroke or other ischemic disease.... Agent: Knobbe Martens Olson & Bear LLP

20100240701 - Tubulysins and processes for preparing: Processes are described for the preparation of tubulysins. The processes are useful for preparing predetermined mixtures of tubulysins, preparing single tubulysins from mixtures of tubulysins, and for converting one tubulysin into a different tubulysin. The tubulysins described herein are useful in treating diseases and disease states that include pathogenic cell... Agent: Barnes & Thornburg LLP

20100240702 - Benzimidazolone chymase inhibitors: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100240703 - Oxyimino compounds and the use thereof: The invention relates to oxyimino compounds of (Formula I), and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is hydrogen, each optionally substituted lower alkyl, lower alkenyl, aryl, heterocyclyl etc. R1 and R2 are each independently hydrogen, each optionally substituted lower alkyl, lower alkenyl,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100240704 - Method of modulating stress-activated protein kinase system: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for... Agent: Marshall, Gerstein & Borun LLP (intermune)

20100240706 - 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones: wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype... Agent: Gardner Groff Greenwald & Villanueva. PC

20100240705 - Substituted enaminocarbonyl compounds used as insecticides: The present application relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100240707 - 1,3,5-trisubstituted triazole derivative: e

20100240708 - Alpha-(n-benzenesulfonamido)cycloalkyl derivatives:

20100240709 - Sulfoximine derivatives as p38 map kinase inhibitors: The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms,... Agent: Ladas & Parry LLP

20100240710 - Use of pyridoxamine to treat and/or prevent disease processes: Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100240711 - Solid preparation comprising npyy5 receptor antagonist: A preparation which can improve solubility of a NPYY5 receptor antagonist in water, even when the NPYY5 receptor antagonist is contained in the preparation at a high content is provided. A solid preparation containing a NPYY5 receptor antagonist, an amorphous stabilizer, and optionally an amorphousization inducing agent. Particularly, when the... Agent: Birch Stewart Kolasch & Birch

20100240712 - Insecticidal compounds: Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100240713 - Aromatic and heteroaromatic compounds useful in treating iron disorders: This invention is directed to compounds of formula (I), wherein m, formula (II), R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed... Agent: SeedIPLaw Group PLLC

20100240714 - Oral composition for dental purposes: A dental composition for oral use, containing a phosphorylated saccharide (a), a cationic bactericidal agent (b) and a solvent (c). By using the dental composition for oral use of the present invention, the adhesion of the bacteria in the oral cavity to the surfaces of the teeth can be suppressed... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100240715 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent: Jones Day

20100240716 - Thiadiazoline derivative: s

20100240719 - Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production: The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with β-amyloid peptide.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100240718 - Novel heteroaryl-substituted acetone derivative, suitable for inhibiting phospholipase a2: The present invention relates to novel heteroaryl-substituted acetone derivatives inhibiting the enzyme phospholipase A2, and pharmaceutical agents comprising said compounds.... Agent: Schmeiser, Olsen & Watts

20100240717 - Novel thiophene derivatives as s1p1/edg1 receptor agonists: The invention relates to thiophene derivatives of formula (I)/their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents wherein: A represents *—CO—CH═CH—, *—CO—CH2CH2—, *—CO—CH2—NH—, wherein the sterisks indicate the bond that is linked to the thiophene group of Formula (I), and R1-R3 are as... Agent: Dickstein Shapiro LLP

20100240720 - Allosteric jnk inhibitors: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents.... Agent: Dla Piper LLP (us)

20100240721 - Synthesis of epothilones, intermediates thereto, analogues and uses thereof: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods... Agent: Choate, Hall & Stewart LLP/mskcc Sloan-kettering Institute For Cancer Research

20100240722 - Fluorine-containing organosulfur compound and pesticidal composition comprising the same: There is provided a fluorine-containing organosulfur compound having an excellent controlling effect m represents 0 or 1; n represents 0, 1 or 2; A represents an optionally substituted 5-membered aromatic heterocyclic group; R1 and R3 are independently represent an optionally substituted C1-C4 chain hydrocarbon group, —C(=G)R5, cyano, halogen or hydrogen;... Agent: Birch Stewart Kolasch & Birch

20100240723 - Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.... Agent: Merck Patent Department (k-6-1, 1990)

20100240724 - Edible film: The present invention relates to an edible film composition comprising a waxy starch hydrolysate, a modified starch and a water-soluble polymer, and an edible film comprising the same. The present edible film may not only have an excellent film forming property, solubility and feeling in the oral cavity, but also... Agent: Dowell & Dowell P.C.

20100240725 - Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation: Disclosed herein are novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives represented by Formula 1, or pharmaceutically acceptable salts thereof. Also disclosed is a pharmaceutical composition for treating or preventing premature ejaculation including the compound. The 1,3-dihydro-5-isobenzofurancarbonitrile derivatives have a short half-life and inhibit the ejaculation process by selectively inhibiting serotonin reuptake via a serotonin... Agent: Lucas & Mercanti, LLP

20100240726 - Compositions for treating amyloid associated diseases: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100240727 - Model for glutamate racemase inhibitors and glutamate racemase antibacterial agents: The increase in antibacterial resistance has created the demand for new antibiotics. The present invention relates to a more potent antibiotic that targets the enzyme glutamate racemase from known glutamate racemase inhibitors. Glutamate racemase catalyses the interconversion of L-glutamate to D-glutamate, making D-glutamate available, which is required for bacterial peptidoglycan... Agent: Vorys, Sater, Seymour & Pease LLP

20100240728 - Co-crystals of pyrrolidinones: The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R1 is a C1-C6 alkyl group. R2 is a C1-C6 alkyl group which is optionally substituted by 1 to 3 halogens or R2 is a C2-C6 alkenyl group.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100240729 - Alpha, beta-unsaturated imidate compound and pesticidal composition containing the same: A and E independently represent a —R1 group, a -L1-R1 group, etc.; G represents a -L2-R1 group, a —S(O)2—R4 group, etc.; X represents a —S—R5 group or a —O—R6 group; Z represents an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; R1 represents an optionally substituted C1-C20 chain... Agent: Sughrue Mion, PLLC

20100240742 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100240743 - Cannabinoid receptor modulator: e

20100240744 - Methods for the treatment of dementia based on apo e genotype: This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behavior problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy.... Agent: Novartis Corporate Intellectual Property

20100240745 - Method of treatment of inflammation in hypertensive patients: The present invention relates to the use of 4-(nitrooxy)-butyl-(S)-2-(6-methoxy-2-naphthyl)-propanoate (naproxcinod) for the treatment of pain and/or inflammation in patients with hypertension treated with renin-angiotensin system blocking agents.... Agent: Arent Fox LLP

20100240746 - Stereoisomers of tricyclodecan-9-yl-xanthogenate: Provided herein are optically active stereoisomers of tricylclodecan-9-yl xanthogenate, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease caused by a virus.... Agent: Jones Day

20100240747 - Motuporamine mimic agents: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.... Agent: Timothy H. Van Dyke

20100240748 - Tetrahydronaphthalen-2-ol derivatives: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression,... Agent: Organon Usa, Inc. C/o Merck

20100240749 - Anesthetic spray composition: An anesthetic spray composition suitable for application to the back of the throat comprising a topical anesthetic and a mucoadhesive polymer.... Agent: Fitzpatrick Cella Harper & Scinto

20100240750 - Catheter lock solution comprising citrate and a paraben: This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention... Agent: Leydig Voit & Mayer, Ltd

20100240752 - Aqueous acidic hard surface cleaning and disinfecting compositions: i

20100240751 - Methods: A perfluoroctanoic acid or a salt or an ester thereof; perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof; or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of... Agent: Patricia A. Limbach Ryan Kromholz & Manion, S.c.

20100240753 - Effective pharmaceutical carrier for poorly bioavailable drugs: The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from 2 to 4 (having... Agent: Meyer Unkovic & Scott LLP

20100240754 - Unsaturated fatty amino acid derivatives and use thereof in dermal cosmetology: The present invention relates to drugs consisting of unsaturated fatty amino-acid derivatives of the general formula (I), and to their pharmaceutically acceptable acid addition salts, in which: X is oxygen or NH, Rn are independently hydrogen or a (C1-C6)alkyl optionally substituted by halogen; R1 is hydrogen, fluorine, chlorine or bromine,... Agent: Birch Stewart Kolasch & Birch

20100240756 - Compounds for treating inflammation and pain: The present invention is directed to a compound of 2-N halo-4-methylsulfonyl-butyric acid, such as 2-N chloro-4-methylsulfonyl-butyric acid, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a pharmaceutical composition comprises the compound and a pharmaceutically acceptable carrier. The present invention is further directed to... Agent: Howrey LLP-ca

20100240755 - Therapeutic and cosmetic compositions for treatment of skin: The present invention is directed to a skin cream containing L-glutathione and methyl sulfone in combination with perfluorodecalin and various vitamins such as Vitamin D and C. The cream can be used to treat cancerous and precancerous diseases found in or on the skin.... Agent: Adam K. Sacharoff Much Shelist Denenberg Ament & Rubenstein

20100240757 - Systems and methods for delivering a fluid drug: Devices and methods for distributing a fluid, e.g., a fluid drug, are disclosed. Fluid-drug distribution can be advantageously utilized to help patients suffering from a disorder that affect fine motor skill usage, e.g., Parkinson's Disease. Some aspects are directed to dosing containers that are adapted to distribute one or more... Agent: Woodcock Washburn LLP

20100240758 - External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic: An external preparation for percutaneous administration which contains a light-sensitive nonsteroidal anti-inflammatory analgesic and a UVA-shielding agent which inhibits the analgesic to cause light toxicity and a light allergy. This external preparation for percutaneous administration, which contains a nonsteroidal anti-inflammatory analgesic, can be prevented, with higher certainty, from causing the... Agent: Edwards Angell Palmer & Dodge LLP

20100240759 - Use of an agent that contains corbamide and/or at least a derivative thereof as a cleaning agent: The invention relates to the use of an agent that contains 5 to 99.9% in weight of carbamide and/or at least a derivative thereof, as a cleaning agent for closed systems, in particular as a dishwasher detergent, as a laundry detergent for washing machines, as an agent for cleaning, sanitizing... Agent: William H. Dippert Eckert Seamans Cherin & Mellott, LLC

20100240760 - Biomarkers for efficacy of aliskiren as a hypertensive agent: A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant... Agent: Dilworth & Barrese, LLP

20100240761 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20100240762 - Sanitizer formulations: The present invention relates to a stable and effective sanitizer formulation for indirect food contact applications. The formulation contains: (a) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (b) a dialkyldimethyl ammonium salt, and (c) a compound selected from the group consisting of... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100240763 - Method to determine and biomarker for treatment efficacy with ssri, snri, and sari antidepressants: The invention provides a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is resistant to treatment with the compound. The method comprises observing whether the genome of the patient contains at least one copy... Agent: Irving N Feit Hoffmann & Baron

20100240764 - Use of s-clenbuterol: The use of S-Clenbuterol for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of S-Clenbuterol leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage... Agent: Gudrun E. Huckett Draudt

20100240765 - Surfactant peroxycarboxylic acid compositions: The present invention relates to compositions including surfactant peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism.... Agent: Ecolab Usa Inc.

20100240766 - Agent for improving carcass performance in finishing hogs: A food supplement for finishing hogs containing astaxanthin is described.... Agent: Mdip LLC

20100240767 - Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof: Disclosed is the cosmeceutical potential of 3,5-dimethoxy-4′-hydroxystilbene in terms of its melanogenesis inhibitory and photo protective activities. Also disclosed does a topical melanogenesis inhibitory composition comprising 0.01 to 50% by weight of 3,5-dimethoxy-4′-hydroxystilbene.... Agent: Sabinsa Corporation

20100240768 - Novel nutraceuticalcompositions containing thymol and/or p-cymene or plant extracts for cognition: The invention relates to a novel nutraceutical composition containing thymol and/or p-cymene, or a plant extract containing thymol or p-cymene as active ingredient(s). The compositions are useful for improvement of cognitive functions and psycho-social status, such as learning, memory and alertness, psychotic stability and maintenance.... Agent: Nixon & Vanderhye, PC

20100240769 - Olive waste recovery: The present invention relates to a process for isolating soluble dietary fibers and valuable polyphenols from olive mill wastewater, wherein the olive mill wastewater is defatted by removing the fat by centrifugation and concentrated by removing the water content. The defatted and dehydrated mixture is extracted using ethanol and an... Agent: Brooks Kushman P.C.

20100240770 - Synthesis and use of colloidal iii-v nanoparticles: A colloidal suspension of III-V semiconductor nanoparticles.... Agent: Steptoe & Johnson LLP

20100240771 - Process for preparing aqueous-alcoholic solution and products based thereon: The present invention relates to the field of food industry, where it may be used for producing alcoholic products, to pharmacology for producing infusions tinctures and extracts or preparations containing aqueous-alcoholic solutions as pharmaceutically acceptable media and also to cosmetology for producing cosmetic products containing aqueous-alcoholic solutions as cosmetically acceptable... Agent: Ladas & Parry LLP

20100240772 - Pigment-free, aqueous polymer dispersions marked with fluorescent dyes, process for their preparation and their use: e

20100240773 - Multifunctional linkers: The present invention relates generally to multifunctional polymeric linkers capable of linking a plurality of biologically active compounds. More particularly, the invention relates to the use of such multifunctional linkers that can effectively present two or more ligands simultaneously to two or more biological targets.... Agent: Mark J. Rosen P.C.

20100240774 - Use of hydrophobin polypeptides as penetration enhancers: The present invention relates to the use of hydrophobin polypeptides as penetration intensifiers.... Agent: Connolly Bove Lodge & Hutz, LLP

20100240775 - Pasteurisation stable starch compositions: The present invention relates to novel compositions having (a) at least one pregelatinized starch and (b) at least one cook-up starch or flour, and which develop upon mixing with water a low cold viscosity, develop no or a low viscosity during the pasteurisation step and develop a significantly higher viscosity... Agent: Fish & Richardson P.C.

20100240776 - Contact lens, method for producing same, and pack for storage and maintenance of a contact lens: A contact lens (4) comprises a solid component capable of imparting shape and structure to said lens, and a liquid component, at least partially contained in the solid component, capable of favouring the compatibility between said lens and the eye of a user of said lens, wherein the liquid component... Agent: Gottlieb Rackman & Reisman PC

  
09/16/2010 > patent applications in patent subcategories. class, title,number

20100234272 - Processes for preparing a polypeptide: The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate. The process comprises: (a) polymerizing a mixture of N-carboxyanhydride of L-tyrosine, N-carboxyanhydride of L-alanine, N-carboxyanhydride of... Agent: Sandoz Inc

20100234273 - Light-activated cation channel and uses thereof: The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention... Agent: Crawford Maunu PLLC

20100234274 - Use of nestafin-1 in the treatment for diabetes: The present invention provides a method of treating diabetes by increasing peripheral nesfatin-1. Peripheral nesfatin-1 can be increased by administration of nesfatin-1, conjugated nesfatin-1 that would not penetrate the blood-brain barrier, or plasmin inhibitors. The present invention also provides a method of screening for an agent that would increase peripheral... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100234275 - Use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium: The present invent ion relates to the use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium. Advantageously, the extracellular hemoglobin is obtained from Annelids. In particular, the invention concerns the use of a high molecular weight... Agent: Birch Stewart Kolasch & Birch

20100234281 - Antibacterial antisense oligonucleotide and method: A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to... Agent: Seed Intellectual Property Law Group PLLC

20100234280 - Antisense antibacterial method and compound: An antibacterial antisense conjugate and method of using the same for treating a bacterial infection in a mammalian host are disclosed. The conjugate includes an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotide contains 10-20 nucleotide bases and has... Agent: Seed Intellectual Property Law Group PLLC

20100234277 - Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease: The present invention relates to methods for treating an anti-inflammatory arthritic disease by coadministering therapeutically effective amounts of an alpha-fetoprotein (or a biologically active fragment thereof) and a disease modifying anti-rheumatic drug (DMARD) to a patient in need thereof. Also disclosed are compositions and kits that include therapeutically effective amounts... Agent: Clark & Elbing LLP

20100234276 - Erythropoietin solution preparation: The present invention relates to an erythropoietin-containing solution preparation containing a poloxamer and having a pH of 6.5 to 7.5. The present invention also relates to a method for quantifying a protein in a trace amount, the method including the following steps: binding a protein sample to a high-intensity fluorescent... Agent: Darby & Darby P.C.

20100234278 - Prophylactic and/or therapeutic agents for peripheral neuropathy: When a pharmaceutical composition for preventing and/or treating peripheral neuropathy caused by chromosomal microtubule inhibition, which comprises erythropoietin as an active ingredient, is administered to patients receiving a microtubule inhibitor as an anticancer agent, such treatment alleviates peripheral neuropathy in the patients and enables increased dosage, prolonged period and increased... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100234279 - Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments,... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20100234282 - System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron: The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into... Agent: King & Spalding

20100234283 - Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use: Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised... Agent: Calfee Halter & Griswold, LLP

20100234284 - Pharmaceutical compositions based on nk2 antagonists for pediatric use: Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.... Agent: Abelman, Frayne & Schwab

20100234285 - Benzofuranyl derivatives: a

20100234296 - Food material for inhibiting osteoclastogenesis:

20100234294 - Identification of new isoforms of the mhc-class i specific receptor cd160 and uses thereof: The present invention concerns an isolated polypeptide comprising a sequence selected in the group comprising SEQ ID NO.7, its orthologs, and derivatives thereof; a polynucleotide comprising a nucleic acid sequence encoding for said polypeptide; a vector comprising said polynucleotide; a host cell genetically engineered with said polynucleotide or with said... Agent: Birch Stewart Kolasch & Birch

20100234289 - Integrin binding rgd-lipopeptides with gene transfer activities: The present invention provides synthesis of a novel series of cationic lipopeptides with integrin-binding RGD functionalities. The invention also provides high L27 (transformed S1 80, mouse sarcoma cells) cell tropic gene transfer properties of these novel RGD-lipopeptides. Since 127 cell surface contains over expressed integrins, the present class of lipopeptides... Agent: Harness, Dickey & Pierce, P.L.C

20100234298 - Matrix protein compositions for induction of apoptosis: Enamel matrix, enamel matrix derivatives and/or enamel matrix proteins or peptides may be used as therapeutic or prophylactic agents for inducing programmed cell death (apoptosis), in particular in the treatment or prevention of cancer or malignant or benign neoplasms.... Agent: Rissman Hendricks & Oliverio, LLP

20100234292 - Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer: The present invention relates to a method of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer in view of the expression of specific nucleic acid sequences in a biological sample.... Agent: Arent Fox LLP

20100234293 - Novel neurotrophic factors: The invention relates to neublastinneurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.... Agent: Fish & Richardson P.C.

20100234286 - Preterm formula: The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance.... Agent: Foley And Lardner LLP Suite 500

20100234300 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer: Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain... Agent: Klarquist Sparkman, LLP

20100234297 - Soluble fiber combinations for weight control and improving parameters of cardiovascular health: A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including... Agent: Chalker Flores, LLP

20100234290 - Stabilized insulin-like growth factor polypeptides: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100234299 - Stable formulation of modified glp-1: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100234288 - Sustained release pharmaceutical composition on the basis of release system comprising an acid-soluble polymer and a ph-dependent polymer: Sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compositions and... Agent: Ladas & Parry LLP

20100234287 - Targeting bacterial suicide pathways for the development of novel antibiotics: The invention provides methods for identifying an agent which prevents or partially prevents an antitoxin from forming a complex with its cognate toxin, comprising contacting a potential agent with a labeled substrate in solution, whereby detection of the label indicates presence of an agent that prevents an antitoxin from forming... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100234295 - Treating alzheimer's disease and osteoporosis and reducing aging: Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase... Agent: Fish & Richardson PC

20100234291 - Preparation and use of low-bleeding anticoagulant fusion protein: Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.... Agent: Fish & Richardson P.C.

20100234301 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100234302 - Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus: The present invention relates to D-amino acid peptides and their use in methods for the diagnosis and/or treatment of immune disorders such as systemic lupus erythematosus.... Agent: Gates & Cooper LLP Howard Hughes Center

20100234303 - Agents, methods and uses: The present invention relates to agents, compositions and methods for use in medicine. In particular, the invention relates to agents related to GnRH peptides.... Agent: Fennemore Craig

20100234304 - Beta sheet tapes ribbons in tissue engineering: There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure.... Agent: Klarquist Sparkman, LLP

20100234305 - Polymeric delivery formulations of leuprolide with improved efficacy: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The... Agent: Schwegman, Lundberg & Woessner, P.A.

20100234306 - Use of a peptide as a therapeutic agent: The present invention is directed to the use of the peptide compound Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent: Winstead PC

20100234307 - Preparation and use of biphenyl amino acid derivatives for the treatment of obesity: This invention relates to certain biphenyl amino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100234308 - Wake-up remedy: A wake-up remedy that for persons with the subjective symptoms of feeling languid after wake-up, having a hard time awaking, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a wake-up remedy containing alanylglutamine or its salt as an active ingredient.... Agent: Day Pitney LLP

20100234309 - Dendrimer compositions: Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.... Agent: Genzyme Corporation Legal Department

20100234310 - Estrogenic compounds and their methods of use: Isolated compounds and combinations of isolated compounds isolated from Epimedium grandiflorum Morr. are estrogenic, and can be used to treat one or more symptoms of menopause and/or ER-positive cancer. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans, for the treatment of... Agent: Wilson, Sonsini, Goodrich & Rosati

20100234311 - Methicillin-resistant staphylococcus aureus active metabolites: This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from Platanus occidentalis. These compounds were found to exhibit anti-bacterial activity against methicillin resistant Staphylococcus aureus (MRSA).... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100234312 - Avermectin derivatives: i

20100234313 - Stabilized micronised particles: The present invention relates to a method for preparing a suspension of micronised particles of a solid organic compound, which method comprises subjecting the solid organic compound to size reduction by wet grinding under pH conditions wherein the intrinsic surface charge of the size-reduced organic compound is sufficient to keep... Agent: Nixon & Vanderhye, PC

20100234315 - Compositions and methods for treating psychiatric and behavioral disorders: In one aspect, the present invention provides methods that comprise administering to a patient an active agent that comprises one or more of protoveratrine A, protoveratrine B, cevadine, veratramine and veratrosine in an amount that is effective to lessen the severity or occurrence of at least one symptom indicative of... Agent: Woodcock Washburn LLP

20100234314 - Idarubicin for the treatment of lymphoma in a dog: The present invention relates to a method of treating a lymphoma in a dog comprising administering to a dog in need of such treatment a therapeutically effective amount of idarubicin or a pharmaceutically acceptable salt thereof.... Agent: Pharmacia & Upjohn

20100234444 - Hindered ester-based biodegradable linkers for oligonucleotide delivery: The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same.... Agent: Lucas & Mercanti, LLP

20100234448 - In vivo production of small interfering rnas that mediate gene silencing: The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100234447 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Mcdermott Will & Emery

20100234445 - Patterns of known and novel small rnas in human cervical cancer: Small RNA sequences that are differentially expressed in SCCC cells are provided. The sequences find use in diagnosis of cancer, and classification of cancer cells according to expression profiles. The methods are useful for detecting cervical cancer cells, facilitating diagnosis of cervical cancer and the severity of the cancer (e.g.,... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100234446 - Rnai modulation of the bcr-abl fusion gene and uses thereof: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.... Agent: Alnylam/fenwick

20100234449 - Immunostimulatory method: The present invention makes it possible to enhance steroid efficacy in a steroid refractory or dependent patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment, by administering an oligonucleotide having the sequence 5 5′-Xm-CG-Yn-3′ in an effective amount to said patient and wherein... Agent: Dla Piper LLP (us)

20100234451 - Lna antagonists targeting the androgen receptor: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising... Agent: Lucas & Mercanti, LLP

20100234450 - Molecular targeting agents: The present invention relates to aptamer conjugates comprising a metal chelating group and to methods of using these aptamers.... Agent: Viksnins Harris & Padys Pllp

20100234316 - Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to... Agent: Merck

20100234317 - Use of difructose anhydride-containing composition: A method for improving bowel movement of a subject desiring such an improvement, includes administering to the subject a defructose anhydride (DFA) in an amount effective to improve bowel movement.... Agent: Knobbe Martens Olson & Bear LLP

20100234319 - Complex of polymeric quaternary ammonium and anionic polymers as a new antimicrobial agent for ophthalmic compositions: Disclosed herein are ophthalmic solutions and methods of using the solutions which comprise a complex of at least one cationic component and an anionic polymer, wherein the complex can be used as an antimicrobial agent. The solutions described have complexes which can be dissolved in aqueous ophthalmic solutions due to... Agent: Abbott Medical Optics, Inc.

20100234320 - Emulsifying compositions based on alkyl polyglycosides and esters: Emulsifying composition containing 1 to 98% of a mixture of alkyl glycosides, a mixture of alcohol esters, a mixture of alcohol esters, 1 to 90% of an alcohol and 0 to 97% of a mixture of alkyl glycoside esters.... Agent: Pearne & Gordon LLP

20100234318 - Ophthalmic composition containing alginic acid or salt thereof: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B)... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100234321 - Oily cosmetic and cosmetic product: A composition is prepared to comprise (a) 50 to 99% by weight of an oily phase that is a liquid at 25° C., (b) 1 to 7% by weight of dextrin (palmitate/2-ethylhexanoate), and (c) 0.001 to 10% by weight of a coloring material and/or pearlescent agent other than a laminated... Agent: Foley And Lardner LLP Suite 500

20100234322 - Treatment of osteoarthritis: There is provided a therapeutic agent for treating osteoarthritis, which is a drug comprising hyaluronan as an active ingredient. The hyaluronan is preferably a tetrasaccharide including two units, with a single unit being -D-glucuronic acid-β-1,3-D-N-acetylglucosamine-β-1,4- (HA4).... Agent: Myers Bigel Sibley & Sajovec

20100234323 - Antimicrobial acids and salts: The invention relates to novel acidic siloxane derivatives, the use, methods of use or processes making use of siloxane derivatives of this type, especially to achieve an anti-microbial, preservative and/or antiadhesive effect, for the protection of articles and/or materials, and a process for the manufacture of the novel compounds. The... Agent: Basf Performance Products LLC Patent Department

20100234324 - Quinazolinamide derivatives: Novel quinazolinamide derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20100234325 - 4-peroxycyclophosphamide use thereof: 4-Peroxycyclophosphamide is provided along with its method of preparation. The compound is useful for treating human cancer, particularly human primary and metastatic malignant brain tumors.... Agent: Robert F. Struck

20100234326 - Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition: The invention relates to pharmacology, medicine and gerontology, in particular to a class of chemical structures (1) which can be used in compositions, in the form of geroprotectors, for extending the life time, decelerating, stopping or for reversing the process of the entirety of the organism's dysfunctions causing the mammal... Agent: Wilmerhale/boston

20100234327 - Novel triazene compounds for the treatment of cancer: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at... Agent: Rankin, Hill & Clark LLP

20100234328 - Antimicrobial compositions and related methods: A liquid antimicrobial composition comprising an organic acid and one or more anionic surfactants is disclosed. In one embodiment, the organic acid is lactic acid and the anionic surfactant is sodium octane sulfonate. In a preferred embodiment, the antimicrobial solution is formulated as a teat dip for lactating animals, particularly... Agent: Lathrop & Gage LLP

20100234329 - Ingestible film composition: The present invention relates to a novel ingestible film composition. More specifically, the invention is directed to a water-based, enzymatically-digested carboxymethylcellulose (CMC-Enz) film composition that is suitable for delivering pharmaceutical drugs, vitamins, natural products and other products to humans and animals. The invention further includes a method for manufacturing the... Agent: Michael Ye Andrews Kurth

20100234330 - Novel estrogenic compounds: wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1... Agent: Myers Bigel Sibley & Sajovec

20100234331 - Hexahydro-cyclooctyl pyrazole cannabinoid modulators: e

20100234332 - Novel quinuclidine derivatives and medicinal compositions containing the same: A compound of formula (I), wherein B is a phenyl ring, a 5 to 10 membered heteroaromatic group containing one or more heteroatoms, or a naphthalenyl. 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, a phenyl group,... Agent: Morrison & Foerster LLP

20100234333 - Novel quinuclidine derivatives and medicinal compositions containing the same: c

20100234334 - Nitric oxide releasing steroids: The invention relates to nitrooxyderivative of corticosteriods of general formula (I) and pharmaceutical acceptable salts or stereoisomers thereof wherein R is the corticosteriod residue of formulas (II): The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological disease and ocular diseases.... Agent: Arent Fox LLP

20100234335 - Neurosteroid compounds: The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions... Agent: J.a. Lindeman & Co. PLLC

20100234336 - Ophthalmic compositions: An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the... Agent: Bausch & Lomb Incorporated

20100234337 - Foaming compositions for hair care: The invention concerns a foaming composition for washing and treating hair and/or scalp essentially characterised in that it contains in an aqueous medium: at least an active principle selected among corticoids and retinoids; at least an anionic surfactant; at least an amphoteric surfactant; and a pro-penetrating... Agent: Nixon & Vanderhye, PC

20100234338 - Chelating agents of metal ions, their methods of preparation and their applications: e

20100234339 - Silver(i) compounds and their use in pharmaceutical compositions for the treatment,prophylaxis and prevention of infections: The present invention provides new Ag(I) complexes with derivatives of nicotinic acid, nicotinamide and related pyridine ligands, and pharmaceutical compositions comprising such Ag(I) complexes for use in the treatment, prophylaxis and prevention of infections. The invention further provides a solvent free method for the synthesis of Ag(I) complexes containing substituted... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100234340 - Substituted spiroamide compounds: wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin... Agent: Crowell & Moring LLP Intellectual Property Group

20100234342 - Ezetimibe compositions: This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife, methods for their preparation, and methods for treatment using the same.... Agent: Hiscock & Barclay, LLP

20100234344 - 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators: The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100234345 - Novel compounds as cannabinoid receptor ligands: e

20100234346 - Novel pyrimidine derivatives: The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)... Agent: Hoxie & Associates LLC

20100234343 - Inhibitors of ion channels: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted aryl sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment... Agent: Townsend And Townsend And Crew, LLP

20100234341 - Substituted pyrimidines as adenosine receptor antagonists: Compounds of formula (I) including pharmaceutically acceptable salts, esters, solvates and stereoisomers thereof, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.... Agent: Cooley LLP Attn: Patent Group

20100234347 - Substituted pteridines substituted with a four-membered heterocycle: m

20100234348 - Compositions and methods for potentiating antibiotic activity: The present invention provides compounds that potentiate the activity of antibiotic agents, particularly quinolones such as norflaxin. The invention further provides compositions, e.g., pharmaceutical compositions, comprising the inventive compounds. The invention also provides compositions comprising an antibiotic (e.g., a quinolone) and a compound that potentiates activity of the antibiotic. The... Agent: Choate, Hall & Stewart LLP

20100234349 - Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and... Agent: Birch Stewart Kolasch & Birch

20100234350 - Platelet adp receptor inhibitors: Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Townsend And Townsend And Crew, LLP

20100234351 - Fused nitrogen-comprising heterocyclic compound: wherein ring A is a 7-membered or 8-membered nitrogen-containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X1 is a group represented by —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100234352 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100234353 - Sulfonylamino-derivatives as novel inhibitors of histone deacetylase: e

20100234354 - Pyridazinone derivatives: Compounds of the formula (I), in which R1, R2, R, R4, R4′ have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100234355 - Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases: m

20100234357 - Benzofuran derivatives:

20100234356 - Compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer, and osteolytic bone... Agent: Millennium Pharmaceuticals, Inc.

20100234360 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100234358 - Neramexane for the treatment of nystagmus: The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate.... Agent: The Firm Of Hueschen And Sage

20100234359 - Treatment of sleep disorders: The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl 4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.... Agent: Fitzpatrick Cella Harper & Scinto

20100234361 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: e

20100234362 - Use of diazoxide for suppressing the plasma insulin level in a mammal: The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or... Agent: Foley And Lardner LLP Suite 500

20100234363 - Heterocyclic derivative having inhibitory activity on type-i 11 data-hydroxysteroid dehydrogenase: e

20100234364 - Ccr2 inhibitors and methods of use thereof: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of... Agent: Brinks Hofer Gilson & Lione

20100234365 - Compounds and compositions as inhibitors of cannabinoid receptor 1 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Genomics Institute Of The Novartis Research Foundation

20100234366 - Use of strobilurins for the treatment of disorders of iron metabolism: Strobilurin derivatives can be employed for the treatment and/or prevention of disorders of iron metabolism in mammals.... Agent: Brinks, Hofer, Gilson & Lione

20100234367 - 7-cycloalkylaminoquinolones as gsk-3 inhibitors: Provided herein are aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.... Agent: Jones Day

20100234368 - Condensed ring compound and use thereof: (wherein all symbols have the same meanings as described hereinbefore). The compound antagonizes cysLT2 and therefore, it is useful as an agent for the prevention and/or treatment of respiratory diseases such as bronchial asthma, bronchial asthma, chronic obstructive pulmonary disease, pneumonectasia, chronic bronchitis, pneumonia (e.g. interstitial pneumonitis etc.), severe acute... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100234369 - 5-cyanothienopyridines for the treatment of tumours: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.... Agent: Millen, White, Zelano & Branigan, P.C.

20100234370 - Pharmaceutical compounds: wherein R1-R3, A and n have any of the values described in the specification; and pharmaceutically acceptable salts thereof; have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer,... Agent: Viksnins Harris & Padys Pllp

20100234371 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof: The invention relates to bicyclic heterocycles of general formula (I), in which Ra, Rb, Rc, Rd, Re and X are as defined in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, in particular, the physiologically-acceptable salts thereof with inorganic and organic acids with useful pharmacological properties, in particular, an... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100234373 - Bis-aryl amide compounds and methods of use: wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions... Agent: Amgen Inc.

20100234372 - Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators: The invention relates to substituted 2-mercaptoquinoline-3-carboxamides, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100234374 - Heterocycle substituted ketone derivatives as histone deacetylase (hdac) inhibitors: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, schizophrenia, inflammatory diseases,... Agent: Merck

20100234375 - Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines: This invention concerns 5-(hydroxymethylene and aminomethylene)pyrimidine derivatives having HIV (Human Immunodeficiency Virus) replication inhibiting properties, to the preparation thereof and to pharmaceutical compositions comprising these compounds.... Agent: Philip S. Johnson Johnson & Johnson

20100234377 - Piperazine compounds for the inhibition of haematopoietic prostaglandin d synthase: and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing.... Agent: Drinker Biddle & Reath (dc)

20100234376 - [4,5']bipyrimidinyl-6,4'-diamine deriviatives as protein kinase inhibitors: d

20100234378 - Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors: Provided are MMP-2, MMP-3, MMP-9, MMP-12 and/or MMP-13 inhibitors having the Formula (I): wherein R2, R3, R4, R5, and Y are as defined herein, which are useful in the treatment and/or prevention of MMP mediated diseases and disorders.... Agent: Viksnins Harris & Padys Pllp

20100234380 - Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor: The present invention relates to processes for preparing phenyl-pyrazoles of Formula (I) and salts and pharmaceutical compositions thereof, useful as modulators of 5-HT2A serotonin receptor activity. The present invention also relates to intermediates used in the processes, and their preparation. The present invention also relates to crystalline forms of 5-HT2A... Agent: Fish & Richardson P.C.

20100234379 - Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity: The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor. Disruption of such signals has been shown to prevent neuronal maintenance... Agent: Alix Yale & Ristas LLP

20100234381 - Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators: A method for predicting the likelihood a mammal will respond therapeutically to a method of treating cancer comprising administering a VEGFR-2 modulator or a dual VEGFR-2/FGFR-1 modulator wherein the method comprises: (a) measuring in the mammal the level of FGF2; (b) either comparing the level of FGF2 in the sample... Agent: Louis J. Wille Bristol-myers Squibb Company

20100234382 - Composition comprising a pde4 inhibitor and a pde5 inhibitor: The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.... Agent: Nath & Associates PLLC

20100234383 - Treating, preventing or ameliorating a hyperproliferative disease/disorder: e

20100234384 - 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20100234385 - Compsition containing biopterin and method for using the same: It is thought that applications and use of tetrahydrobiopterin (BH4), which is used as a pharmaceutical, will expand due to its superior efficacy. However, in addition to BH4 being extremely expensive, since it is unstable with respect to oxidation, applications other than pharmaceuticals are considered to be difficult. Further, it... Agent: Birch Stewart Kolasch & Birch

20100234386 - Quinoxaline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20100234387 - Sulfonylated tetrahydroazolopyrazines and their use as pharmaceuticals: wherein R1, R2a, R2b, R3a, R3b, R4, R8, R9a, R9b, R10, R11, A, B, W1, W2 and W3 have the meanings defined herein, pharmaceutical compositions containing such compounds, a method for the preparation of such compounds, and the use of such compounds for treating or inhibiting various types of pain... Agent: Crowell & Moring LLP Intellectual Property Group

20100234388 - Substituted pde5 inhibitors: Provided herein are substituted PDE5 inhibitors of Formula (1), and processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of hypertension, erectile dysfunction, and/or the inability to maintain improved erectile function. The compounds are deuterated tadalafil derivatives.... Agent: Global Patent Group - Apx

20100234389 - Amide compound: o

20100234391 - N-substituted piperazines:

20100234390 - Novel compound and their use: The present invention provides novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The novel compounds are useful as antibacterial agents in the treatment of conditions such as nosocomial pneumonia, community acquired pneumonia, infections... Agent: Ladas & Parry LLP

20100234392 - 4-sulfonylpiperidine derivatives: wherein R1 is C1-6 alkyl, C3-8 cycloalkyl, or the like; R2 is phenyl, heteroaryl, or the like; Q is N or CH; and M1, M2, M3 and M4 are each independently hydrogen or C1-6 alkyl, or alternatively M1 together with M2 or M3 forms —CH2-CH2- or the like, or M4... Agent: Merck

20100234393 - Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension: The present invention relates to the use of a vasopeptidase inhibitor for the preparation of a medicament for use in the treatment and/or prevention of PAH.... Agent: Stites & Harbison PLLC

20100234394 - Substituted benzimidazoles and methods of their use: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and... Agent: Novartis Vaccines And Diagnostics Inc.

20100234395 - Ureide derivative and pharmaceutical application thereof: Discloses is a pharmaceutical agent comprising an ureide derivative represented by the formula: or a pharmaceutically acceptable salt thereof as an active ingredient. The ureide derivative or the pharmaceutically acceptable salt thereof is useful for the relief of a pain or the treatment or prevention of neurogenic pain.... Agent: Birch Stewart Kolasch & Birch

20100234397 - Enzyme inhibitors: s

20100234396 - Tetrhydropyridoindole derivatives: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.... Agent: Hunton & Williams LLP Intellectual Property Department

20100234398 - Insecticidal n-substituted (heteroaryl)alkyl sulfilimines: N-Substituted (heteroaryl)alkyl sulfilimines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100234399 - Agent for overcoming resistance to anti-cancer agent: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.... Agent: Nixon Peabody, LLP

20100234400 - Compounds that maintain pluripotency of embryonic stem cells: The present invention relates to methods and compositions for culturing embryonic stem (ES) cells. The methods relate to growing the ES cells in the presence of small molecules of formula (I) that maintain the pluripotency/self-renewal of the cells without feeder cells and LIF in serum-free conditions. These methods in part... Agent: Genomics Institute Of The Novartis Research Foundation

20100234401 - 6,9-disubstituted purine derivatives and their use for treating skin: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.... Agent: Fitch Even Tabin & Flannery

20100234402 - Methods and compositions for treating spinal muscular atrophy: This invention provides methods of treating and abrogating spinal muscular atrophy by administering an antioxidant. Additionally, the invention provides a method of protecting the SMN protein by administering an antioxidant.... Agent: Pearl Cohen Zedek Latzer, LLP

20100234403 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent: Merck

20100234404 - P-38 kinase inhibitors: Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α, and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100234405 - Pyrimidine nucleoside derivatives and salts thereof: m

20100234406 - Compounds and compositions as c-kit and pdgfr kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.... Agent: Genomics Institute Of The Novartis Research Foundation

20100234407 - Preventives/remedies for myeloma tumor and method for diagnosing the same: The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100234408 - Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment of NF, and to a method of treating non-cancerous, benign brain tumors, especially for the curative and/or prophylactic treatment... Agent: Novartis Corporate Intellectual Property

20100234409 - Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity: Compounds of the formulae (I) and (II): (wherein Q, X, E, G1, G2, R2, R3, R4, R5, R6 and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic... Agent: Merck

20100234410 - Hydrate for medical purposes: The present invention relates to [7-[(7S)-7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hemihydrate. This hemihydrate is stable and easy to prepare, and has excellent properties for a pharmaceutical bulk powder.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100234411 - New combination for the treatment of respiratory diseases: The present invention relates to novel pharmaceutical compositions based on telmisartan 1 and anticholinergics 2 processes for preparing them and their use for the treatment of respiratory diseases.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100234412 - Buprenorphine derivatives and uses thereof: Ester derivatives of the phenolic hydroxyl group of buprenorphine can be used in the treatment of opiate dependency and/or moderate to severe pain. The esters have an enhanced bioavailability, an enhanced duration of action, and a reduced abuse potential.... Agent: Fish & Richardson PC

20100234413 - Compositions and methods for prophylaxis and treatment of addictions: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic... Agent: Seed Intellectual Property Law Group PLLC

20100234414 - Use of loratadine 10mg for the prevention of upper respiratory inflammation/sinus infections caused from exposure to bacteria and viruses on airplane flights: The invention relates to the use of Loratadine 10 mg prior to flying to prevent upper respiratory inflammation and sinus infections caused from exposure to bacteria and viruses while flying. People are packed together in airplanes, which has dry and polluted air. Flying is one of the more common places... Agent: Mariangela Lazear

20100234415 - Indole derivatives as crth2 receptor antagonists: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.... Agent: Merck

20100234416 - Use of huperzine for disorders: Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100234418 - Compounds and uses thereof: N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, N-[3-(4-ethynyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods... Agent: Foley & Lardner LLP

20100234417 - Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers: A hetero-dimeric or hetero-oligomeric receptor, comprising at least one thyrotropin releasing hormone receptor subunit associated with at least one orexin receptor subunit.... Agent: Marshall, Gerstein & Borun LLP

20100234419 - Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators: The invention relates to substituted 3-aminoisoxazolopyridines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100234420 - Tetrahydroquinoline derivatives for treating post-traumatic stress disorders: e

20100234421 - Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators: The invention relates to substituted 3-amino-2-mercaptoquinolines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100234422 - Sulfonylated heterocycles useful for modulation of the progesterone receptor: Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus;... Agent: Howson & Howson LLP / Wyeth LLC

20100234424 - Derivatives of n-phenyl(piperidine-2-yl) methyl benzamide preparation method thereof and applications of same in therapeutics: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100234423 - Triazolothiadiazole inhibitor of c-met protein kinase: The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Inc.

20100234425 - 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors: e

20100234426 - Phenylpropionamide compounds and the use thereof: The invention relates to phenylpropionamide compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A, B, R1, R2, R3, R4 and R5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat, prevent... Agent: Purdue Pharma, Lp

20100234427 - 1-phenethylpiperidine derivatives and their use as opioid receptor ligands: e

20100234428 - Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators: The invention relates to substituted 2-mercapto-3-aminopyridines, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100234429 - Substituted nicotinamides as kcnq2/3 modulators: The invention relates to substituted nicotinamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100234430 - Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments: Methods and pharmaceutical compositions for protecting pharmaceutical compounds (or drugs) in acidic environments are provided. Methods of treatment using formulations capable of protecting pharmaceutical compounds in acidic environments are also provided. Formulations provided generally comprise a therapeutically effective amount of at least one pharmaceutical compound, and a pharmaceutically acceptable protectant.... Agent: Steven F. Weinstock Abbott Laboratories

20100234431 - Pyrrolidine compounds: t

20100234432 - Substituted 6-phenylnicotinic acids and their use: The present application relates to novel substituted 6-phenylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, in particular... Agent: Bayer Healthcare LLC

20100234433 - Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof: This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100234434 - Flavivirus inhibition by sultams and related compounds: Disclosed herein are compounds, compositions and methods for treating or ameliorating flavivirus infections. This is particularly important because the present disclosure provides methods for treating flavivirus infections for which there is no effective vaccine.... Agent: Klarquist Sparkman, LLP

20100234435 - Cycloalkylamino acid derivatives: s

20100234436 - Pest control agent in form of stable suspension: Disclosed is a pest control agent in the form of a suspension, which exhibits excellent dispersion stability for a long time without forming a hard cake due to settling and separation of solid particles or without losing fluidity due to gelation even when a cationic pest control active ingredient and/or... Agent: Oliff & Berridge, PLC

20100234437 - Pesticide compositions: This invention is related to the field of compositions useful in the control of pests that eat cellulose, such as, termites, where said composition is compacted and where said composition comprises alpha-cellulose, water, and a pesticide.... Agent: Dow Agrosciences LLC

20100234440 - Novel crystal of substituted phenylalkanoic acid ester and process for producing the same: i

20100234438 - Therapeutic agents: The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20100234439 - Therapeutic agents: The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20100234441 - Novel compounds: e

20100234443 - Combinations of statins and anti-obesity agent: Co-therapy of an anti-obesity agent, a statin, is disclosed along with fixed combinations thereof. Atorvastatin and orlistat are preferred as the various components.... Agent: Irving M. Fishman

20100234442 - Compositions and methods for treatment and prevention of cardiovascular disease: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100234452 - Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100234453 - Pharmaceutical composition containing phenanthrenequinone-based compound for intestine delivery system: Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular phenanthrenequinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an... Agent: Birch Stewart Kolasch & Birch

20100234454 - Treatment of cnidaria intoxication: The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.... Agent: Clark & Elbing LLP

20100234455 - Histone deacetylase inhibitors: Hormone refractory metastatic disease can be treated with an oxyamide-containing compound through the inhibition of HDAC1 or HDAC2.... Agent: Steptoe & Johnson LLP

20100234456 - Apoptosis promoters: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100234457 - Aqueous microemulsions containing organic insecticide compounds: m

20100234458 - Process for the production of fatty acid alkyl esters:

20100234459 - Medicall use of 3-(2,2,2,-trimethylyhdrazinium) propionate hdrogen fumarate and dihydrogen phosephate: Novel medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts for the manufacture of a medicament for prevention and therapy of atherosclerosis.... Agent: The Firm Of Hueschen And Sage

20100234460 - Compositions comprising a c2-c14 carboxylic acid and a surfactant for treating hoof diseases: Germicidal compositions containing at least one carboxylic acid combined with at least one nonionic or anionic surfactant, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the... Agent: Hovey Williams LLP

20100234461 - Compositions for improved oxidative status in companion: A food composition that is useful for increasing antioxidant levels in the body is provided having increased levels of sulfur-containing amino acids, such as methionine, cysteine, or mixtures thereof. Methods of using these compositions for increasing antioxidant levels in the body in mammals, especially in companion animals, are also provided.... Agent: Colgate-palmolive Company

20100234462 - Topical composition: The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.... Agent: Novartis Consumer Health, Inc.

20100234465 - Administration of intravenous ibuprofen: An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.... Agent: Davidson, Davidson & Kappel, LLC

20100234464 - Compounds for the treatment of metabolic disorders: 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.... Agent: Wellstat Management Company. LLC

20100234463 - Method for identifying modulators of gamma secretase or notch: The present invention relates to methods for high throughput screening to identify selective modulators of γ-secretase. Such modulators selectively block γ-secretase activity without affecting Notch cleavage and signaling. Said methods employ the use of high content screening methodologies to measure and quantify the translocation of the Notch intracellular domain (NICD)... Agent: Merck

20100234466 - Compositions and methods for reducing body fat: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.... Agent: Wolf Greenfield & Sacks, P.C.

20100234467 - Methods for improving bioavailability of a renin inhibitor: The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a ε-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an MDR1... Agent: Novartis Corporate Intellectual Property

20100234468 - Novel process: The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(−)-2-benzhydrylsulfinylacetamide and S-(+)-2-benzhydrylsulfinylacetamide respectively.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100234469 - New crystals of a benzoylbenzeneacetamide derivative: The invention relates to 2-amino-3-benzoylbenzeneacetamide, i.e. nepafenac, crystals having reduced chargeability, to processes for the preparation thereof, and to the use thereof for preparing pharmaceutical formulations.... Agent: Leydig Voit & Mayer, Ltd

20100234470 - Instillation administration of capsaicinoids for the treatment of pain: This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100234471 - Lidocaine tape preparation: The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine contant of 10 w/w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100234472 - Nitric oxide releasing derivatives of paracetamol: The present invention particularly relates to novel nitrate esters of paracetamol. The nitrate esters of paracetamol are prepared by reacting the paracetamol with dihaloalkyl compound and followed by reaction with silver nitrate to obtain the corresponding nitrate ester derivatives. The nitrate esters of paracetamol are useful as analgesic, anti-inflammatory agents.... Agent: Ladas & Parry LLP

20100234473 - Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-n-alkyl-3-phenylpropylamines: A new process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N,alkyl-3-phenylpropylamines from cinnamyl chloride via N-alky-3-phenylprop-2-en-1-amine has been developed.... Agent: Arent Fox LLP

20100234474 - Method and composition for evenly applying water soluble actives: A method and composition for evenly applying water soluble actives is described. The method includes applying a composition with a HIPE to skin and generating a film having a hydrophilic surface so that composition and active can be evenly applied.... Agent: Unilever Patent Group

20100234475 - Foaming alcohol compositions with selected dimethicone surfactants: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.... Agent: Mckee, Voorhees & Sease, P.L.C

  
09/09/2010 > patent applications in patent subcategories. class, title,number

20100227793 - Compositions and methods for treating amyotrophic lateral sclerosis: The invention relates to methods for preserving fast axonal transport in a cell affected by Amyotrophic Lateral Sclerosis by inhibiting pathogenic superoxide dismutase-induced increases in p38α activity. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin-1, as well as methods for monitoring treatment... Agent: Licata & Tyrrell P.C.

20100227791 - Compounds having antitumor activity: e

20100227792 - Phospholipid and protein tablets: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin... Agent: Casimir Jones, S.c.

20100227794 - Smart contrast agent and method for detecting transition metal ions and treating related disorders: The present disclosure provides smart contrast agents for transition metals and a method of using the same. The smart contrast agents include a core peptide and a first labeling group attached to a first end of the core peptide. The smart contrast agents can also include a second labeling group... Agent: Stein Mcewen, LLP

20100227796 - Insulin derivatives: The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100227795 - Insulin formulations for rapid uptake: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional... Agent: Pabst Patent Group LLP

20100227797 - Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives: There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin,... Agent: Morrison & Foerster LLP

20100227799 - Simultaneous photodynamic therapy and photo induced polymerization: Described herein are methods and compositions for the combined treatments of photodynamic therapy and photo-induced polymerization. The wavelength of light needed to accomplish both therapies can be different or can be the same. In one embodiment, the photodynamic therapy is performed first and the photo-induced polymerization is performed thereafter. In... Agent: Medtronic Vascular, Inc.IPLegal Department

20100227798 - Use of the staudinger ligation in in vivo assembly of a biologically active compound: The invention provides methods and tools for the in vivo self-assembly of drugs. This makes it possible to reduce problems associated with the lack of selectivity, reduced solubility and other disadvantages of intact drugs.... Agent: Philips Intellectual Property & Standards

20100227801 - Pharmaceutical compositions: This invention relates to combinations comprising 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gammahydroxymethylleucine)cyclosporine, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and certain nucleoside analogues, and their use in the treatment of hepatitis C virus.... Agent: Buchanan, Ingersoll & Rooney PC

20100227800 - Triazole derivatives as kinase inhibitors: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders.... Agent: O'brien Jones, PLLC

20100227813 - A method of using interferon-like potein zcyto20 (il-28a) or zcyto22(il-28b) to treat hepatitis b: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department

20100227809 - Combination treatment for metabolic disorders: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula, I or a pharmaceutically acceptable... Agent: Wellstat Management Company. LLC

20100227820 - Effect of porcine sheath proteins on the regeneration activity of periodontal ligament: The purpose of this study was to identify the periodontal regeneration factors in enamel protein shown to induce cementum- and osteo-promotive activities in vivo. The cementum regeneration (CR), a part of periodontal regeneration, was examined by using experimental cavities prepared in a buccal dehiscence dog model. The CR activity was... Agent: Makoto Fukae

20100227811 - Farnesylamine derivatives and methods of use: The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of ras-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100227804 - Gel-forming composition for medical use, administration device for the composition, and drug release controlling carrier: It is an object of the present invention to provide a gel-forming composition which permits on-site administration and can form a gel exhibiting prescribed strength and sustained drug release, devices for the administration thereof, and a kit for medical use. A gel-forming composition which is composed of the first composition... Agent: Myers Wolin, LLC

20100227808 - Human kunitz-type inhibitor with enhanced antifibrinolytic activity: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2).... Agent: Mueting, Raasch & Gebhardt, P.A.

20100227814 - Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes: The present invention relates to inhibitors of GSK-3 and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes and Alzheimer's disease. In addition, the invention relates to molecules... Agent: Ropes & Gray LLP

20100227817 - Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused... Agent: Ronald I. Eisenstein

20100227810 - Method for diagnosing staphylococcal infections: s

20100227812 - Method of supplementing the diet and ameliorating oxidative stress:

20100227802 - Methods and materials relating to paqr polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to PAQR polypeptides. Other aspects of the invention include vectors containing processes for producing novel human PAQR polypeptides, and antibodies specific for such polypeptides.... Agent: Arca Biopharma, Inc

20100227823 - Methods for regulating angiogenesis and vascular integrity using trk receptor ligands: The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor... Agent: Nixon Peabody LLP - Patent Group

20100227805 - Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases: Soluble molecules are provided. Thus, for example, provided is a soluble molecule which comprises a heterologous amino acid sequence conjugated to a CCR5 amino acid sequence being capable of binding a CCR5 ligand, and wherein the molecule is devoid of an N-terminus domain of CCR5. Also provided are pharmaceutical compositions... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100227821 - Monitoring and modulating hgf/hgfr activity: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.... Agent: Fish & Richardson PC

20100227803 - Polypeptides having antimicrobial activity and polynucleotides encoding same: The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20100227818 - Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia: Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”).... Agent: Foley And Lardner LLP Suite 500

20100227819 - Serum-free cell culture medium for mammalian cells: The invention relates to a process for the manufacturing of a protein in mammalian cells cultured in a serum-free medium.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100227815 - Site-specific pegylated linear salmon calcitonin analogues: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.... Agent: Banner & Witcoff, Ltd.

20100227822 - Targeted delivery of botulinum toxin to the sphenopalatine ganglion: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.... Agent: Allergan, Inc.

20100227806 - Use of a ghrelin agonist to improve catabolic effects of glucocorticoid treatment: A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, specifically [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.... Agent: Rines And Rines

20100227807 - Use of gelsolin to diagnose and treat inflammatory desease (stossel): The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).... Agent: Wolf Greenfield & Sacks, P.C.

20100227816 - Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission: The present invention relates to a peptide analogue of glucagon-like peptide-1 (7-36), which is useful to prophylactically prevent, improve, or reverse the diminished cognitive function associated with these types of disorders, by increasing (or sustaining) the LTP of synaptic transmission. Moreover, sustaining LTP may find utility in the prophylaxis of... Agent: Licata & Tyrrell P.C.

20100227825 - Peptides and peptide mimetics to treat cancer: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable... Agent: Weaver Austin Villeneuve & Sampson LLP

20100227824 - Pharmaceutical peptides for the treatment of inflammatory diseases: The invention provides pharmaceutical compositions comprising at least a portion of a chemokine receptor or a G-protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100227827 - Method of increasing tryptophan and nicotinamide levels in vivo: Novel methods of increasing the biosynthesis of aromatic amino acids and compositions containing the precursors of said aromatic amino acids or nicotinamide and methods of use thereof. In addition, methods of monitoring the therapeutic effects of an anti-oxidant therapy by measuring serum protein thiols as a surrogate or predictor of... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100227828 - New synergistic phytochemical composition for the treatment of obesity: Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are... Agent: Kramer & Amado, P.C.

20100227826 - Stable flavonoid solutions: A stable flavonoid solution comprising (i) at least one flavonoid or flavonoid derivative selected from the group consisting of luteolin, myricetin, baicalin, baicalein, silymarin and kushenol, (ii) a mixture of alkyl glycols of two to seven carbon atoms, (iii) a polyol ether and (iv) an antioxidant.... Agent: Louis C. Paul Louis C. Paul & Associates, PLLC

20100227829 - Motilide polymorphs: The invention provides polymorphs of a motilide having a structure represented by formula Ia... Agent: Fitzpatrick Cella Harper & Scinto

20100227830 - Use of escin: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.... Agent: Fulbright & Jaworski L.L.P.

20100227831 - Compositions and methods for cancer treatment: wherein R1 is selected from the group consisting of methyl, alkyl, cholesteryl, aryl and aralkyl, R2 is selected from the group consisting of hydrogen, methyl, alkyl, and a water-soluble cation, Y is selected from the group consisting of oxygen, sulfur, carbon and nitrogen, and R3 is a cytotoxic agent. Methods... Agent: Williams Mullen

20100227909 - Compositions comprising mir34 therapeutic agents for treating cancer: In one aspect, the invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100227908 - Diagnostic, prognostic and treatment methods: The present invention relates generally to diagnostic and prognostic protocols for schizophrenia and its manifestations including sub-threshold phenotypes and states thereof. Profiling and stratifying individuals for schizophrenia and its various manifestations also form part of the present invention as well as monitoring and predicting efficacy of therapeutic, psychiatric, social or... Agent: Knobbe Martens Olson & Bear LLP

20100227910 - Gene fusion targeted therapy: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.... Agent: Casimir Jones, S.c.

20100227907 - Method of treating pain by using opioids and camkiv inhibitors: A method of treating chronic pain in a mammal is provided comprising the steps of inhibiting CaMKIV in the mammal and administering to the mammal a therapeutically effective amount of an opioid.... Agent: Valentine A Cottrill Susan Tandan

20100227911 - Rna interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or... Agent: Merck

20100227912 - Rna interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity... Agent: Merck C/o Sirna Therapeutics, Inc.

20100227915 - Compositions and methods for inhibiting expression of a gene from the jc virus: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to... Agent: Alnylam/fenwick

20100227913 - Nanoprobes for detection or modification of molecules: The disclosure provides probes for one or more target molecules. In particular examples, the probes include a molecular linker and first and second functional groups linked and spaced by the molecular linker, wherein the functional groups are capable of interacting with one another or with the target biomolecule in a... Agent: Klarquist Sparkman, LLP (ott-nih)

20100227914 - Rna antagonist compounds for the inhibition of apo-b100 expression: Short oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with Apo-B100 expression are provided. The oligonucleotides comprise deoxyribonucleosides and locked nucleic acids.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100227832 - Modulation of telomere length in telomerase positive cells and cancer therapy: Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size... Agent: Juan Carlos A. Marquez C/o Stites & Harbison PLLC

20100227833 - Novel nucleoside analogs for treatment of viral infections: This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.... Agent: Banner & Witcoff, Ltd.

20100227834 - Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy: i

20100227835 - Substituted liposaccharides useful in the treatment and prevention of endotoxemia: Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.... Agent: Mccarter & English, LLP & Eisai Co.

20100227836 - Parenteral administration of a glucosamine: Materials and methods for local delivery of a glucosamine are provided to facilitate bone and cartilage growth.... Agent: Edwards Angell Palmer & Dodge LLP

20100227837 - Mobile self-spreading biocides: Each R1 is C1-C3 alkyl group or fluoridated C1-C3 alkyl group. The value n is a positive integer. Each R2 is alkylene group or polyethylene glycol group. Y1 is hydrogen, quaternary ammonium-containing group, or phenol-containing group. Y2 is quaternary ammonium-containing group or phenol-containing group. The quaternary ammonium-containing group is non-aromatic... Agent: Naval Research Laboratory Associate Counsel (patents)

20100227838 - Combination therapy for treating cancer and diagnostic assays for use therein: The present disclosure relates to a combination of therapeutic agents for use in treating a patient a subject suffering from cancer. In addition, the present disclosure also relates to diagnostic assays useful in classification of patients for treatment with one or more therapeutic agents.... Agent: Jones Day

20100227839 - Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate: A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci... Agent: Knobbe Martens Olson & Bear LLP

20100227840 - Use of 25-hydroxy vitamin d3 to improve male animal fertility: The present invention relates to the use of 25-hydroxy vitamin D3 to improve animal fertility. More particularly, the invention relates to the use of 25-hydroxy vitamin D3 for improving the quality of semen and/or conception rate in animals including men. In a preferred embodiment the invention relates to the use... Agent: Nixon & Vanderhye, PC

20100227841 - Patient populations and treatment methods: The invention provides 17α-ethynylandrost-5-ene-3β,7β,17β-triol for use in methods to treat, e.g., pre-diabetic hyperglycemia or type 2 diabetes patients having a fasting blood glucose level of at least 110 mg/dL or a post prandial glucose level of at least about 140 mg/dL an optionally a body mass index of >29.9, wherein... Agent: Harbor Biosciences, Inc.

20100227842 - Methods for treating ocular inflammatory diseases: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes... Agent: Mcdermott Will & Emery LLP

20100227843 - Beta-lactamase-resistant cephalosporin ester compounds and salts of thereof: m

20100227844 - Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease: The present invention relates to methods of treating Alzheimer's Disease and Alzheimer's Disease related disorders comprising administration of a compound of structural formula: (I), or a pharmaceutically acceptable salt thereof, as a monotherapy or in combination with an anti-Alzheimer's Disease agent. The present invention further provides for pharmaceutical compositions, medicaments,... Agent: Merck

20100227847 - Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis;... Agent: Pepper Hamilton LLP

20100227846 - Substituted pyrazole derivative: wherein R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R3 is... Agent: Edwards Angell Palmer & Dodge LLP

20100227845 - Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases: The present invention relates to compounds represented by Formula (I), Formula (II) and Formula (III) and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.... Agent: Merck

20100227849 - Leukemia treatment method and composition: A method of inducing high anti-leukemia activity responsive to the combination of hydroxamic acid analogue histone deacetylase inhibitors and PKC412 against human acute leukemia characterized as expressing phosphorylated (p)FLT3 kinase by a novel flow cytometry-based assay.... Agent: Bryan Cave LLP

20100227848 - Oxo bridged diazepan orexin receptor antagonists: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck

20100227850 - Methods for preventing and treating microbial infections by modulating transcription factors: The current invention is based, inter alia, on the finding that the transcription factor MarA, and homologues of MarA, e.g., Rob and SoxS, are virulence factors. Accordingly, the invention discloses methods for screening compounds for their ability to modulate these virulence factors. The invention further describes methods for treating and... Agent: Mccarter & English, LLP Boston

20100227851 - Method of preventing and/or treating a neurodegenerative disease by administering an extract of lycoris chejuensis and/or a compound isolated therefrom: Provided are novel use of an extract of Lycoris chejuensis or a compound isolated therefrom for inhibition of β-amyloid production and/or prevention, improvement and/or treatment of a neurodegenerative disease, more specifically a β-amyloid production inhibitor, and/or a composition for prevention or treatment of a neurodegenerative disease containing one or more... Agent: LexyoumeIPGroup, LLC

20100227852 - Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors: The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.... Agent: The Firm Of Hueschen And Sage

20100227853 - Inhibitors of cyclic amp phosphodiesterases: Recombinant fission yeast cells and methods of using them are described, which provide for identification of chemical and biological inhibitors or activators of a target exogenous phosphodiesterase (PDE). The invention provides, in some aspects, compounds that inhibit cAMP PDE activity and compositions that include such compounds. The invention, in part,... Agent: Wolf Greenfield & Sacks, P.C.

20100227854 - Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors: The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.... Agent: Townsend And Townsend And Crew, LLP

20100227855 - Helix 12 directed non-steroidal antiandrogens: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form.... Agent: Ostrolenk Faber Gerb & Soffen

20100227856 - Novel compounds: e

20100227857 - 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors: The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.... Agent: Philip S. Johnson Johnson & Johnson

20100227858 - Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases: A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use intherapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.... Agent: Astrazeneca R&d Boston

20100227859 - Tricyclic compounds as matrix metalloproteinase inhibitors: The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12,... Agent: Wyeth LLC Patent Law Group

20100227860 - Disalt inhibitors of il-12 production: This invention relates to disalt nitrogen-heteroaryl inhibitors of IL-12 production, and related methods and pharmaceutical compositions.... Agent: Edwards Angell Palmer & Dodge LLP

20100227861 - Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors: i

20100227862 - Diaza-spiro [4.5] decanes useful as pesticides: A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I) wherein Y is... Agent: Syngenta Crop Protection, Inc., Patent And Trademark Department

20100227863 - Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds: m

20100227864 - 5-membered heterocyclic derivative and use thereof for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100227865 - Oligomer-beta blocker conjugates: The invention provides Beta-blocker drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the Beta-blocker... Agent: Nektar Therapeutics

20100227866 - Tetrahydroisoquinolin-1-one derivative or salt thereof: [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the... Agent: Fitzpatrick Cella Harper & Scinto

20100227867 - Compounds, formulations, and methods for treating or preventing inflammatory skin disorders: wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms... Agent: Hoffmann & Baron, LLP

20100227868 - Treatment methods with brimonidine: Disclosed herein are therapeutic methods related to brimonidine.... Agent: Allergan, Inc.

20100227869 - Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands: This invention relates to novel enantiopure azabicyclo pyridazinyloxy derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as... Agent: Birch Stewart Kolasch & Birch

20100227870 - Novel compounds: i

20100227871 - Nicotinic receptor agonists for the treatment of inflammatory diseases: This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary... Agent: Buchanan, Ingersoll & Rooney PC

20100227872 - Pyrazine derivatives: i

20100227873 - Nitrogen-containing heterocyclic compounds and methods of use thereof:

20100227874 - Reduction of oxidative stress damage during or after exercise: Use of at least 25 mg of a polyphenol for the preparation of a product to be consumed before or during exercise for reducing oxidative stress damage during or after exercise.... Agent: K&l Gates LLP

20100227875 - Methods for detection of biological substances: The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of... Agent: Wilson, Sonsini, Goodrich & Rosati

20100227876 - Methods of reducing side effects of analgesics: The invention provides for compositions and methods of reducing pain in a subject by administering a combination of mu-opioid receptor agonist, kappa1-opioid receptor agonist and a nonselective opioid receptor antagonist in amounts effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The invention also... Agent: Marshall, Gerstein & Borun LLP

20100227877 - New camptothecin derivatives and uses thereof: The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100227879 - Liquid formulations for treatment of diseases or conditions: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but... Agent: Morrison & Foerster LLP

20100227878 - Noscapine analogs and their use in treating cancers, including drug-resistant cancers: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer... Agent: Intellectual Property / Technology Law

20100227881 - 1,7-naphthyridine derivatives as p38 map kinase inhibitors: New inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100227880 - Chemical compounds: w

20100227882 - Clopidogrel salt and polymorphic forms thereof: The invention relates to methyl(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate or a polymorphic form and/or a hydrate and/or a solvate thereof, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100227883 - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20100227884 - Amide compounds and plant disease controlling method using same:

20100227885 - Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP... Agent: Jones Day

20100227886 - Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP... Agent: Jones Day

20100227887 - Pyridine-2-yl carboxylic acid amides: h

20100227888 - Modulators of cftr: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20100227889 - Benzimidazole derivatives: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein R, X and Y are as disclosed in the specification, suitable for the treatment of osteoporosis.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100227890 - Polymorphs of esomeprazole salts: The present invention relates to a high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention further provides an improved and commercially viable process for preparation of high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention also provides an improved process... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100227891 - Threshold blood omeprazole concentration is 50 ng/ml for the maintenance of intragastric ph of at least 4.0 after oral dosing with cma-omeprazole, agn 201904-z: Dosage forms of sodium {4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate, and methods of use of the dosage forms are disclosed herein.... Agent: Goodwin Procter LLP Patent Administrator

20100227892 - Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20100227893 - Insecticide compositions: t

20100227894 - Benzamide factor viia inhibitors useful as anticoagulants:

20100227895 - Method for treating equine laminitis: A method for the treatment and preventative care of equine laminitis includes effective administration of the amino acid L-tyrosine, alone, or in conjunction with choline bitartrate, niacin, and/or d-calcium pantothenate to regulate and restore hormonal balance, blood pressure and normal catecholamine synthesis. Tyrosine administration fosters proper vasculation in the equine's... Agent: Marvin A. Glazer

20100227896 - Use of vitamin pp compounds: Vitamin PP compounds and compounds with anti-pellagra activity such as nicotinic acid and nicotinamide are useful for the reduction, elimination, and prevention of side-effects of immunosuppressive and anti-cancer chemotherapy and diagnosis, especially those induced by the use of substituted pyridine carboxamides of formula I. Combinations containing compounds of formula I... Agent: Scully Scott Murphy & Presser, PC

20100227897 - Composition for controlling colorado potato beetles: The present invention relates to an insecticidal composition suitable for use in controlling Colorado potato beetles comprising zeta-cypermethrin and a second insecticide selected from the group consisting of acetamiprid and fipronil.... Agent: Patent Administrator Fmc Corporation

20100227898 - Novel microbiocides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100227899 - Process for the treatment of bacterial infections using 2-phenyl-1,2-benzisoselenazol-3(2h)-one 1-oxide: The subject invention demonstrates a novel antibacterial activity for 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide, and is directed to the treatment of bacterial infections by administration of an effective amount of said compound. Bacterial infections include those infections which are either systemic or superficial in nature. The treatment... Agent: Blase C. Billack

20100227900 - Use of sulphur-containing heteroaromatic acid analogues as bactericides: e

20100227902 - Bis-aryl sulfonamides: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.... Agent: K. Shannon Mrksich, Ph.d. C/o Brinks Hofer Gilson & Lione

20100227901 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is... Agent: Wellstat Management Company. LLC

20100227903 - Polymer formulations of cetp inhibitors: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.... Agent: Merck

20100227904 - Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.... Agent: Alcon

20100227905 - Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye: The present invention relates to development of efficacious pharmaceutical compositions in the form of aqueous solutions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.... Agent: Alcon

20100227906 - C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers: The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for... Agent: Innovar, LLC

20100227917 - Eye drop containing dibenz[b,e]oxepin derivative: The present invention provides an eye drop comprising: a dibenz[b,e]oxepine derivative or a salt thereof and a polyvalent weak acid, an acidic amino acid or an amide thereof, a basic amino acid or an amide thereof, or the salt thereof, and the like, for the purpose of providing an eye... Agent: Edwards Angell Palmer & Dodge LLP

20100227916 - N-desmethyl-doxepin and methods of using the same to treat sleep disorders: The invention relates to desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.... Agent: Knobbe Martens Olson & Bear LLP

20100227918 - Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria: The present invention relates to a novel antimicrobial compound of lactoquinomycin that is highly effective against many antibiotic-resistant gram-positive bacteria; namely, methicillin-resistant and vancomycin-resistance Staphylococcus aureus, vancomycin-resistant Enterococcus faecilis and Mycobacteria. The present invention also relates to a fermentation process of culturing a Streptomyces strain to prepare the antimicrobial compound... Agent: Venable LLP

20100227919 - Dioxaspiroketal derivatives, process for their preparation and uses thereof: The invention relates to dioxaspiroketal derivatives of formula (I): wherein R, is selected from the group consisting of H, straight or branched chain C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, cycloalkyl, heterocyclyl, phenyl, optionally para-, meta- or ortho-substituted with 0 to 3 substituent selected from halogen, —CN, —NH2, —OH, —NO2, COOR2,... Agent: Hedman & Costigan, P.C.

20100227920 - Aldehyde dehydrogenase inhibitors as novel depigmenting agents: The present invention provides methods and compositions for reducing pigmentation.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100227921 - Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof: Prodrugs of tapentadol with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with the tapentadol prodrugs are provided herein. Prodrugs having side chains of valine, leucine, isoleucine and glycine amino acids and mono-, di- and tripeptides thereof are preferred. Additionally, methods... Agent: Mcdermott Will & Emery LLP

20100227922 - Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container... Agent: K&l Gates LLP

20100227923 - Preventive/remedy for urinary calculosis: The present invention relates to a prophylactic/therapeutic drug for urolithiasis containing as an active ingredient L-aldonic acid, a salt thereof, or a lactone form thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100227924 - Method for producing polyunsaturated fatty acids: The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypeptide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for... Agent: Connolly Bove Lodge & Hutz, LLP

20100227925 - Sensitizing compound and method for increasing sexual sensitivity: A clitoral sensitizing agent includes a base, L-citrulline, and a promotional vehicle.... Agent: Mayback & Hoffman, P.A.

20100227926 - Disinfectant delivery system, and method of providing alcohol-free disinfection: A disinfectant delivery system and method of providing alcohol-free disinfection to a body to be disinfected, as well as a method of infection reduction by preparation of a patient before an invasive procedure. A blended cloth comprising first fibers and second fibers is provided with the first fibers generally being... Agent: William M. Lee, Jr. Barnes & Thornburg

20100227927 - Salts of tramadol and naproxen and their crystal forms in the treatment of pain: The present invention concerns salts of Tramadol and Naproxen and their crystalline forms, and compositions thereof, for the treatment of pain, as well as their process for preparation.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100227928 - Non-steroidal anti-inflammatory ophthalmic compositions: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.... Agent: Mcdermott Will & Emery LLP

20100227929 - Transdermal compositions: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.... Agent: Scully Scott Murphy & Presser, PC

20100227931 - Antifungal composition: The present invention provides the antifungal composition, containing the compound (a) selected from specific quaternary ammonium salts and specific amine oxides and the sequestering agent (b) having a calcium-chelating constant of 4 to 12 at a mass ratio (a)/(b) of 0.01 to 10.... Agent: Birch Stewart Kolasch & Birch

20100227930 - Ecological quaternary ammonium disinfectant cleaner: The present invention concerns an ecological benzineless quaternary ammonium disinfectant cleaner comprising quaternary ammonium compound(s) either (i) including octyl decyl dimethyl ammonium chloride, dioctyl dimethyl ammonium chloride and didecyl dimethyl ammonium chloride, in a relative proportion of about 2:1:1 by weight, or (ii) consisting essentially of quaternary ammonium compounds consisting... Agent: Choate, Hall & Stewart LLP

20100227932 - Patch: A Bisoprolol patch, wherein the skin penetration rate of Bisoprolol after 24 hours is 15 to 60% of the maximum skin penetration rate thereof, shows a little difference between the maximum level of the concentration in blood and the minimum level thereof in repeated administration and, therefore, scarcely exhibits side... Agent: Licata & Tyrrell P.C.

20100227933 - Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitors: The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active... Agent: Stroock & Stroock & Lavan LLP

20100227934 - Therapeutic compounds and methods of use: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.... Agent: Edwards Angell Palmer & Dodge LLP

20100227935 - Class of terpene-derived compounds having an antibiotic activity, compositions containing the same and uses thereof: The present invention relates to a new class of terpene-derived compounds having an antibiotic activity and of the formulae (I) or (II) in which A is selected from NR1, O, S, CR2R3 or R—(CH2)n—R′, wherein R and R′ represent independently NH, O, S or CH2, and in which R1, R2... Agent: Birch Stewart Kolasch & Birch

20100227936 - Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase: Methods of inhibiting phagolysosomal fusion in patients infected with a microorganism involve the administration of a 4-hydroxyphenylpyruvate dioxygenase (HPPD)-inhibiting compound, such as 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) to the patient. A HPPD-inhibiting compound administered in an amount effective to enhance phagolysosomal fusion in the macrophages or neutrophils of the patient reduces or treats... Agent: Michael Best & Friedrich LLP

20100227937 - Antimicrobial adhesive system: An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated... Agent: Nawrocki, Rooney & Sivertson Suite 401, Broadway Place East

  
09/02/2010 > patent applications in patent subcategories. class, title,number

20100222250 - Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same: Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide,... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20100222251 - Mixture comprising an amylin peptide and a protracted insulin: The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and a protracted insulin peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100222252 - Deshydroxy vancomycin, the preparation, pharmaceutical composition and the use: The present invention provides a deshydroxy vancomycin compound,a method of its preparation and a pharmaceutical composition comprising a pharmaceutically effective amount of the deshydroxy vancomycin and the use of the said composition in the preparation of drugs for the treatment of susceptible bacteria infections. The method includes the following steps:... Agent: Emerson, Thomson & Bennett, LLC

20100222253 - Methods for extracting platelets and compositions obtained therefrom: This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.... Agent: Don D. Cha

20100222254 - Stabilization of clostridium botulinum neurotoxin complex: A stable composition including a non-covalent complex of a botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation... Agent: Winston & Strawn LLP Patent Department

20100222255 - Peptoid oligomers, pharmaceutical compositions and methods of using the same: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum... Agent: Klauber & Jackson

20100222256 - Novel polypeptide anti-hiv agent containing the same: The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or... Agent: Jordan And Hamburg LLP

20100222257 - Substituted phenethylamines: Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100222276 - protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications: The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses... Agent: Knobbe Martens Olson & Bear LLP

20100222266 - A method of using interferon-like protein zcyto21(il-29) to treat hepatitis b: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-a at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20100222268 - Antibiotic peptides: This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide... Agent: Fanelli Strain & Haag PLLC

20100222263 - Atap peptides, nucleic acids encoding the same and associated methods of use: Disclosed herein are nucleic acid sequences that encode pro-apoptotic polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research... Agent: Mccarter & English, LLP Hartford Cityplace I

20100222279 - Composition for animal consumption and method for reducing map kinase activity: This invention is directed generally to compositions (including foods nutritional supplements, treats, and toys) for animal consumption, particularly compositions that comprise omega-3 and omega-6 polyunsaturated fatty acids, and particularly compositions that tend to aid in reducing mitogen-activated-protein (“MAP”) kinase activity in animals. This invention also is directed generally to methods... Agent: Colgate-palmolive Company

20100222259 - Compositions for enhancing the production of ppar and/or ppar-associated factors: The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222271 - Formulation to improve gastrointestinal function: The subject invention provides compositions, and uses thereof, that improve gastrointestinal function. The compositions and methods of the subject invention are particularly advantageous for use with neonates because they can be used to stimulate development of the immature intestine in order to provide an enhanced ability to absorb nutrients and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222274 - Glycosylation-deficient hepatocyte growth factor: The invention provides a modified glycosylation-deficient HGF and a production method thereof. The glycosylation-deficient HGF is produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100222265 - Heparin binding epidermal growth factor (hb-egf) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation: The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration... Agent: Marshall, Gerstein & Borun LLP

20100222270 - Heterocyclic compounds as crth2 receptor antagonists: This application relates to a compound of Formula ! (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an antagonist of receptor CRTH2, as well as a process for its preparation and intermediates therefor.... Agent: Foley And Lardner LLP Suite 500

20100222269 - Improved derivatives of amylin: The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100222273 - Modified cry35 proteins: This invention provides modified, insecticidal Cry35 proteins with enhanced properties as compared to wild-type Cry35 proteins. The modifications to these proteins were based in part on analysis of the atomic coordinates and three-dimensional (3D) structure of the ˜45 kDa 149B1 protein and other proteins in the Cry35 class. The subject... Agent: Baker & Daniels LLP- Dow Agrosciences

20100222261 - Peptidic antagonists of class iii semaphorins/neuropilins complexes: The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100222272 - Pharmaceutical compositions for the treatment of tnf-alpha related disorders: The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100222267 - Recombinant transferrin mutants: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding... Agent: Novozymes North America, Inc.

20100222277 - Regulation of food preference using glp-1 agonists: GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100222262 - Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions: Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3-cyclopentadione compounds are described.... Agent: Mcdermott Will & Emery

20100222275 - Therapeutic agent for vitiligo and method of accelerating pigmentation: m

20100222258 - Tnf antagonist and tnf inhibitor containing it as an effective ingredient: The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100222278 - Use of leptin for the prevention of excess body weight and composition containing leptin: The invention relates to the use of leptin in the preparation of an ingestible composition for children from nursing infants to adolescents, comprising leptin at a concentration greater than 50 ng/kg for the prevention of excess weight and/or the complications associated therewith. The invention comprises the use of a fully-... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100222264 - Use of rgd-enriched gelatine-like proteins for inhibition of cancer metastasis: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Ip Patent Docketing K&l Gates LLP

20100222260 - Uses of pegylated albumin: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.... Agent: Amster, Rothstein & Ebenstein LLP

20100222280 - Peptides with the capacity to bind to transforming growth factor beta 1 (tgf-beta 1): The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression,... Agent: Moore & Van Allen PLLC

20100222281 - Delivery of hydrophilic drugs: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222282 - Method of diagnosis and method of treatment: The present invention relates to a method for diagnosing higher susceptibility for diseases and conditions associated with low levels of AKG in a human or animal comprising the following steps: a) obtaining a biological sample from said human or animal; b) measuring the alpha-ketoglutaric acid (AKG) level in the biological... Agent: Schwegman, Lundberg & Woessner, P.A.

20100222283 - Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal desease: Methods are provided for treating and preventing renal disease in a subject by administering a gamma secretase inhibitor or a Notch pathway inhibitor to the subject.... Agent: Amster, Rothstein & Ebenstein LLP

20100222284 - Composition for inhibiting the onset of arteriosclerosis and inhibition method: [Means for Resolution] The composition for inhibiting the onset of arteriosclerosis is characterized by comprising D-psicose as an active ingredient for an antiatherogenic action. The antiatherogenic action as described above includes an action of inhibiting or reducing the expression of a chemokine or a cytokine related to arteriosclerosis in vivo... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100222285 - Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation: A specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation is disclosed. This rare sugar is provided as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food. The proliferation of vascular endothelial cells is controlled utilizing the vascular endothelial cell... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100222286 - Receptor modulators exhibiting neuroprotective and memory enhancing activities: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological... Agent: Townsend And Townsend And Crew, LLP

20100222287 - Therapeutic cancer treatments: Provided are methods for treating prostate cancer by administering a therapeutically effective amount of a hedgehog inhibitor.... Agent: Fish & Richardson P.C.

20100222288 - Stabilized formulation of ivermectin feed premix with an extended shelf life and method of making the same: The invention relates to a stabilized premix feed or feed-like formulation that has an extended shelf life due to a decrease of the degradates of the active ingredient by controlling the amount of an already existing stabilizer in the formulation. The feed premix is used in the treatment or prophylaxis... Agent: Judy Jarecki-black Ph.d., J.d.

20100222290 - Methods for concomitant administration of colchicine and macrolide antibiotics: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.... Agent: Cantor Colburn, LLP

20100222289 - Methods for diagnosis and treatment of chronic fatigue syndrome: Methods for diagnosing and treating chronic fatigue syndrome in a patient comprise, for example, testing tissue of the patient for the presence of nucleic acid molecules of one or more CFS-causing herpesviruses and one or more non-herpesvirus infectious agents, and diagnosing the patient's CFS as (a) caused by one or... Agent: Venable LLP

20100222291 - Medicinal forms of phospholipid preparations and methods for their preparation: A method for producing an encapsulated medicinal form of a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, said method comprising mixing a solution of phospholipid in an organic solvent with glycyrrhizic acid or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier substance... Agent: Intellectual Property / Technology Law

20100222413 - Chemically modified oligonucleotides for use in modulating micro rna and uses thereof: This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100222409 - Compositions and methods for inhibiting expression of pro-apoptotic genes: The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier.... Agent: Cooper & Dunham, LLP

20100222408 - Methods and compositions for treatment of cystic fibrosis: The present invention relates to compounds and methods of inhibiting p97/valosin-containing protein and compounds and methods of inhibiting gp78, the compounds and methods being useful for the treatment of a disorder comprising a IκB/NFκB mediated chronic inflammatory response component, for example cystic fibrosis.... Agent: Edwards Angell Palmer & Dodge LLP

20100222412 - Modulation of glucocorticoid receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for treatment of diseases... Agent: Mcdermott Will & Emery

20100222410 - Nuclease compositions and methods: The present invention generally relates to various nucleases and uses thereof, and in some cases, to the UPF0054 protein superfamily. Members of the UPF0054 protein superfamily, such as the E. coli protein YbeY, may possess RNase activity and may be involved in certain important cellular processes. Disruption of YbeY activity... Agent: Wolf Greenfield & Sacks, P.C.

20100222414 - Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof: Modification formats having modified nucleotides are provided for siRNA. Short interfering RNA having modification formats and modified nucleotides provided herein reduce off-target effects in RNA interference of endogenous genes. Further modification formatted siRNAs are demonstrated to be stabilized to nuclease-rich environments. Unexpectedly, increasing or maintaining strand bias, while necessary to... Agent: Life Technologies Corporation C/o Intellevate

20100222407 - Triblock copolymers for cytoplasmic delivery of gene-based drugs: The invention features a triblock copolymer including a hydrophilic block; a hydrophobic block; and a positively charged block capable of reversibly complexing a negatively charged molecule, e.g., a nucleic acid, wherein the hydrophobic block is disposed between the hydrophilic block and the positively charged block. Desirably, the triblock copolymer is... Agent: Clark & Elbing LLP

20100222411 - Vhz for diagnosis and treatment of cancer: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility... Agent: David S. Resnick

20100222418 - Combination products for treating cancer: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the... Agent: Pepper Hamilton LLP

20100222420 - Compositions and methods for inhibiting ezh2: The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.... Agent: Casimir Jones, S.c.

20100222417 - Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues: The present invention relates to the delivery of oligonucleotide across and into epithelial tissues by conjugating the oligonucleotide with a lipophile and/or coadministering with a penetration enhancer. In particular, the present invention provides a composition comprising a conjugated siRNA, which are advantageous for the in vivo delivery of nucleic acids... Agent: Nixon Peabody LLP

20100222416 - Diagnostic marker and therapeutic target for cancer: The present invention, in general, relates to use of nm23H1-B gene for diagnosing cancer susceptibility and metastatic progression in colon/colorectal cancer. In particular, the present invention relates to identifying the alteration in the expression of nm23H1-B gene on treatment with chemotherapeutic agents for diagnosing cancer susceptibility and metastatic progression in... Agent: Ladas & Parry LLP

20100222415 - Method to diagnose, predict treatment response and develop treatment for psychiatric disorders using markers: The disclosure provides methods and compositions useful for identifying a subject's predisposition or diagnosis of a mental disorder, methods of screening for agents useful for treating such a disorder and methods of treatment thereof.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20100222419 - Method to inhibit cell growth using oligonucleotides: Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or... Agent: Howrey LLP - East

20100222292 - Method for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.... Agent: Mcdermott Will & Emery LLP

20100222294 - Formulations of atp and analogs of atp: This disclosure provides solutions and compositions (e.g., pharmaceutical solutions and compositions) containing adenosine 5′-triphosphate (ATP) or an analog thereof. In addition, it features methods of making and using the solutions and compositions.... Agent: Fish & Richardson P.C.

20100222293 - Modulation of sperm motility: Provided are methods of enhancing the fertility of mammalian spermatozoa involving contacting the spermatozoa with adenosine 5′-triphosphate and method of fertilization using spermatozoa treated in this way.... Agent: Fish & Richardson P.C.

20100222295 - Anti-viral pyrimidine nucleoside derivatives: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O,... Agent: Stites & Harbison PLLC

20100222296 - Pyrimidines, such as uridine, in treatments for patients with bipolar disorder: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.... Agent: Clark & Elbing LLP

20100222297 - Cell wall derivatives, their preparation process, and use thereof: In a first aspect, the present invention relates to a method for isolating cell wall derivatives from fungal or yeast biomass. According to this method, chitin polymers or chitin-glucan copolymers can be obtained. In another aspect, the invention relates to a method for preparing chitosan from chitin. The invention further... Agent: Clark & Brody

20100222298 - Spill resistant formulations containing clays: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20100222300 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100222299 - Compound: The present invention involves tetrahydroisoquinoline compounds and their use in the inhibition and/or prevention of tumor growth.... Agent: Hunton & Williams LLP Intellectual Property Department

20100222301 - Topical drug for treatment and/or prevention of diabetic neuropathy, microangiopathy and diabetic and non diabetic ulcers and wound infection: The various embodiments herein provide a topical drug composition for the treatment of diabetes-related complications. According to one embodiment herein, the composition comprises of a compound belonging to a group of chemicals containing borates. Boric acid is used as the base material of the drug. Boric acid is dissolved in... Agent: Choobin & Choobin Consultancy L.l.c Barry Choobin

20100222302 - Novel antibacterial compounds: e

20100222303 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic... Agent: Seed Intellectual Property Law Group PLLC

20100222304 - Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis: Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the modulation of glycogeno lysis or glycolysis... Agent: Aestus Therapeutics Inc.

20100222305 - Complexes of phosphate derivatives: There is provided a composition comprising the reaction product of: a) one or more phosphate derivatives of one or more hydroxylated actives; and b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these... Agent: Michael Best & Friedrich LLP

20100222306 - Class of gamma delta t cells activators and use thereof: The present invention relates to a new class of compounds having γδ T cells activating properties referred to herein as angelyl or tiglyl phosphoesters, compositions comprising any of these compounds and methods for regulating an immune response in a subject comprising the step of administering these compounds.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222307 - Vitamin d and vitamin d analogs or derivatives as new anti-hypertensive agents: Methods and compositions to suppress renin expression and blood pressure in mammals are disclosed. Vitamin D and its analogues and derivatives, including Gemini compounds, are negative regulators of renin synthesis and blood pressure. Renin expression and plasma angiotensin II production were increased several fold in vitamin D receptor (VDR) null... Agent: Barnes & Thornburg LLP

20100222310 - Benzodiazepine compositions for treating epidermal hyperplasia and related disorders: The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal... Agent: Casimir Jones, S.c.

20100222308 - Ophthalmic, otic or nasal pharmaceutical composition and the use thereof: The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for... Agent: Steptoe & Johnson LLP

20100222309 - Skin property-improving therapeutic agent comprising a morphinan derivative or any of its pharmacologically permissible acid addition salts as an active ingredient: A skin property-improving therapeutic agent includes a compound having a specific morphinan skeleton typified by a compound 1 represented by the following formula (II) or any of its pharmacologically permissible acid addition salts as an active ingredient:... Agent: Ip Group Of Dla Piper LLP (us)

20100222311 - Solid formulations of crystalline compounds: Described herein are formulations of active pharmaceutical ingredients, where the active pharmaceutical ingredients or drugs are included in a solid suspension with one or more solid additives. The formulations described herein are useful for formulating any drug or active pharmaceutical ingredient, including those that have limited solubility in organic and/or... Agent: Barnes & Thornburg LLP

20100222312 - Delayed-release glucocorticoid treatment of asthma: The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100222313 - Pharmaceutical compositions-4: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of... Agent: Harbor Biosciences, Inc.

20100222314 - Aqueous-based pharmaceutical composition: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the... Agent: Fox Rothschild LLP Sanofi-aventis

20100222315 - Patient populations and treatment methods: The invention provides 17α-ethynylandrost-5-ene-3β, 7β, 17β-triol for use in methods to treat, e.g., hyperglycemia or diabetes patients having a body mass index of at least about 31 (≧30.5, ≧31 or ≧32), wherein the patients are not concurrently treated with metformin and optionally another antidiabetic agent. In these methods, the patient... Agent: Harbor Biosciences, Inc.

20100222316 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other... Agent: Paul D. Yasger Abbott Laboratories

20100222320 - Triazole derivatives for treating alzheimer's disease and related conditions: Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.... Agent: Merck

20100222317 - Azetidine derivatives as glyt1 inhibitors: The present invention relates to compounds of formula (I); and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof, as GIyT1 inhibitors for treating neurological and psychiatric disorders.... Agent: Merck

20100222318 - Compounds useful as inhibitors of atr kinase: e

20100222319 - Nicotinamide derivatives, preparation thereof and therapeutic use thereof:

20100222323 - Imidazopyrazine syk inhibitors: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100222321 - Inhibitors of akt activtiy: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck

20100222325 - Inhibitors of bruton's tyrosine kinase: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100222322 - Non-nucleoside reverse transcriptase inhibitors: Indole compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the... Agent: Merck

20100222324 - Substituted indole compounds: In which R8, R9a, R9b, R10, R11, R200, R210, A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least... Agent: Crowell & Moring LLP Intellectual Property Group

20100222326 - New heterocyclic derivatives useful for the treatment of cns disorders: The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100222327 - Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100222329 - 2-acylaminothiazole derivative or salt thereof: A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.... Agent: Danielle L. Herritt, Esq. Mccarter & English, LLP

20100222328 - 2-cyclopropyl-thiazole derivatives: The invention relates to selected 2-cyclopropyl-thiazole derivatives of the formula (I) wherein B, Y and R1 are as described in the description; to salts and especially pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100222330 - New compounds: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.... Agent: Fish & Richardson PC

20100222331 - New compounds: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100222332 - Pyrazolo-pyrazines derivatives used as g protein inhibitors: The invention relates to pyrazolo-pyrazines derivatives of the general formula (I) in which the radicals Z, R1, R2, R3 and R4 represent various variable groups, X is a sulphur atom or a selenium atom, and n is an integer equal to 1 or 2. These compounds are inhibitors of G... Agent:

20100222333 - Excipient preservatives and pharmaceutical compositions comprised thereof: Topically applicable pharmaceutical compositions contain at least one pharmaceutically active agent and an effective antimicrobial amount of a preservative excipient mixture and devoid of such amount of known preservative(s) as would otherwise itself impart an effective antimicrobial action thereto.... Agent: Buchanan, Ingersoll & Rooney PC

20100222334 - Pharmaceutical formulation of valsartan: The present invention relates to a pharmaceutical composition in a form of suspension for oral administration comprising valsartan or its pharmaceutically acceptable salts and at least one or two or more of the components selected from glycerol or syrup or the mixture thereof, a preservative, a buffer system and a... Agent: Novartis Corporate Intellectual Property

20100222335 - Process for the preparation of n,n'-disubstituted oxabispidines: There is provided a process for the preparation of a sulfonic acid salt of formula I, or a solvate thereof, which process comprises hydrogenating a sulfonic acid salt of formula II, or a solvate thereof; in the presence of a solvent system consisting essentially of water, a C3-5 secondary alkyl... Agent: Pepper Hamilton LLP

20100222336 - Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication: The present invention relates to single enantiomer compounds of formula (1), where the moieties n, A, R1, R2, R3, m, and Y can have the meanings stated in the claims and in the description, methods for the production thereof, and the use thereof as medication, in particular as medication to... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100222337 - Fungicidal composition containing carboxylic acid amide derivative: Conventional fungicidal compositions have had practical problems such that either a preventive effect or a curative effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upon the application site, and a fungicidal composition to overcome such problems... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100222338 - Beta-secretase modulators and methods of use: wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including... Agent: Amgen Inc.

20100222340 - Substituted pyrido [1,2-a] isoquinoline derivatives: e

20100222339 - Thiazole pyrazolopyrimidines crf1 receptor antagonists: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.... Agent: Eli Lilly & Company

20100222341 - Piperidine and piperazine derivatives: Compounds of the formula (I), in which R1, R2, R3, D, G, Q and W have the meanings indicated in claim (1), can and be employed for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100222343 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone... Agent: Elmore Patent Law Group, PC

20100222342 - Pyrrolopyrazole, potent kinase inhibitors: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.... Agent: Pfizer Inc

20100222344 - 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors: r

20100222345 - Novel compounds as antagonists or inverse agonists for opioid receptors: This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100222346 - 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy: The present invention relates to 4-benzylaminoquinolines of the formula (I) or physiologically tolerated salts thereof. The invention relates to pharmaceutical compositions comprising such quinolines, and the use of such quinolines for therapeutic purposes. The quinolines are GIyTI inhibitors.... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100222347 - Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient: [wherein R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, a C1-6 alkyl group, or the like; R4, R5, R6, R7, R8, R9 and R10 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or the like; A represents N—R11 or an oxygen atom; R11... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100222349 - Quinoline derivatives used to treat inflammatory and allergic diseases: h

20100222348 - Quinolinone derivatives as parp inhibitors:

20100222350 - Phenyl, pyridine, quinoline, isoquinoline, naphthyridine and pyrazine derivatives:

20100222351 - Methods of controlling insects: The invention relates to a method of controlling insects in the family Nitidulidae using the compound 4,5-di-hydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one and also encompasses the use of compositions comprising 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one for controlling Nitidulidae, in particular pollen beetles as well as the preparation of said compound and/or compositions for use in controlling Nitidulidae. In particular,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100222352 - Compounds and methods for the treatment of viruses and cancer: The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14... Agent: Coleman Sudol Sapone, P.C.

20100222353 - Aminophthalazine derivative compounds: The invention pertains to new aminophthalazine compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods... Agent: Pfizer Inc Mary J Hosley

20100222354 - Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain: The invention provides methods for treating and/or preventing neuropathic pain by administering to patients therapeutically effective amounts of AMPA receptor antagonists and aldose reductase inhibitors. The neuropathic pain may be diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists and aldose... Agent: Clark & Elbing LLP

20100222356 - Furazano '3, 4-b! pyrazines and their use as anti-tumor agents: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100222355 - Quinolizidinone m1 receptor positive allosteric modulators: The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent: Merck

20100222357 - Indol-3-y-carbonyl-piperidin and piperazin-derivatives: wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100222358 - Octahydro-pyrrolo[3,4-b]pyrrole derivatives: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.... Agent: Paul D. Yasger Abbott Laboratories

20100222359 - Compositions, synthesis, and methods of utilizing quinazolinedione derivatives: The present invention provides quinazolinedione derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.... Agent: Fenwick & West LLP

20100222360 - Treatment of malignant peripheral nerve sheath tumors: e

20100222362 - N-oxides of n-phenyl-2-pyramidine-amine derivatives: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment... Agent: Novartis Corporate Intellectual Property

20100222361 - 2-acylaminothiazole derivative or salt thereof: A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.... Agent: Danielle L. Herritt, Esq., Mccarter & English, LLP

20100222363 - Bicyclic derivatives as p38 inhibitors: New bicyclic derivatives of formula (I); wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100222364 - Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia: Disclosed is the use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid or its pharmaceutically acceptable salt for the prevention of hair loss; for hair regrowth, hair toning and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia.... Agent: The Webb Law Firm, P.C.

20100222368 - N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and therapeutic use thereof: s

20100222366 - Piperidine derivatives as modulators of chemokine receptor activity: The present application describes modulators of MIP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases,... Agent: Louis J. Wille Bristol-myers Squibb Company

20100222367 - Pyrazine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100222365 - Substituted triazole deriviatives as oxytocin antagonists: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc. Patent Department

20100222369 - Treatment for dry eye conditions: The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3 adenosine receptor (A3AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is... Agent: The Nath Law Group

20100222370 - Methods of treating cancer: The invention relates to the treatment of cancer using an inhibitor of 5′-methylthioadenosine phosphorylase (MTAP). The invention particularly relates to the treatment of prostate cancer and head and neck cancer.... Agent: Amster, Rothstein & Ebenstein LLP

20100222371 - Prevention of surgical adhesions: The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans... Agent: David S. Resnick

20100222372 - Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient: e

20100222373 - Crystalline form of bis [(e)-7-[4-(4-fluoro-phenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.... Agent: Morgan Lewis & Bockius LLP

20100222375 - Pharmaceutical composition comprising trospium chloride for once-a-day administration: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.... Agent: Arent Fox LLP

20100222374 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Feldman Gale, P.A.

20100222376 - Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders: The present invention relates to the use of chelerythrine and chelerythrine analogs in pharmaceutical compositions for the treatment of prefrontal cortical cognitive disorders, including bipolar disorder, among others.... Agent: Cantor Colburn, LLP

20100222377 - Bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic acetylcholine receptors: Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20100222378 - 2-heteroarylcarboxylic acid amides: The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.... Agent: Edwards Angell Palmer & Dodge LLP

20100222380 - Modified chalcone compounds as antimitotic agents: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an... Agent: Banner & Witcoff, Ltd.

20100222379 - Novel histone deacetylase inhibitors: Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular... Agent: Oliff & Berridge, PLC

20100222381 - Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors: o

20100222382 - Esters of compounds in the leptomycin family:

20100222384 - Iminosugars and methods of treating arenaviral infections: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Arenaviridae family using iminosugars, such as DNJ derivatives.... Agent: Foley And Lardner LLP Suite 500

20100222383 - Iminosugars and methods of treating viral diseases: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.... Agent: Foley And Lardner LLP Suite 500

20100222385 - Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist: The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve... Agent: Townsend And Townsend And Crew, LLP

20100222386 - Substituted piperidines: A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine... Agent: Steve T. Zelson, Esq. Novo Nordisk Of North America, Inc.

20100222387 - 3-fluoro-piperidine t-type calcium channel antagonists: The present invention is directed to 3-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck

20100222388 - Enhanced migraine treatments based on ghrelin mimetics: The present invention relates to method of enhancing the absorption of migraine medications and thereby treating migraines by co-administering to a subject in need thereof an effective amount of a ghrelin mimetic or pharmaceutically acceptable salt, hydrate or solvate thereof and at least one migraine medication selected from a serotonin... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100222389 - Novel microbiocides: Compounds of the formula (I), in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100222391 - Benzimidazole compound crystal: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100222390 - Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors: Disclosed herein are liquid compositions comprising a therapeutically effective concentration of a prodrug of a sulfonyl-containing proton pump inhibitor, wherein said compositions have a pH of from 3 to 7.3. Solid compositions related thereto are also disclosed. Methods of delivering a proton pump related thereto are also disclosed. Compositions comprising... Agent: Goodwin Procter LLP Patent Administrator

20100222392 - Insecticidal compounds: A compound of formula (I) wherein A1, A2, A3, A4, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100222394 - Method for producing pyrazol-3-yl-benzamide derivative: c

20100222393 - Muscarinic receptor antagonists: Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy,... Agent: Ranbaxy Inc.

20100222395 - Compounds capable of activating cholinergic receptors: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100222396 - 4-aryl-butane-1,3-diamides: m

20100222397 - Use of succinate dehydrogenase inhibitors for controlling powdery mildew primary infections: The present invention relates to the use of succinate dehydrogenase Inhibitors for controlling powdery mildew primary infections in crops and to a method for controlling those primary infections.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100222398 - Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent: Birch Stewart Kolasch & Birch

20100222399 - Thiazolidinedione analogues for the treatment of hypertension: The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R1 and R4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R2 is halo, hydroxy,... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz And Cohn

20100222400 - F1f0-atpase inhibitors and related methods: The present invention relates to a family of guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.... Agent: Casimir Jones, S.c.

20100222401 - Compositions and methods for treating pathologic angiogenesis and vascular permeability: Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis by modulating a signaling pathway delineated herein are described. Moreover, methods for producing and screening compounds and compositions capable of modulating the signaling pathway described herein, inhibiting vascular permeability, and inhibiting pathologic angiogenesis are also provided.... Agent: Stoel Rives LLP - Slc

20100222402 - Method of manufacturing 4'-[[4-methyl-6-(1-methyl-1h-benzimidazol-2-yl)-2-propyl-1h-benzimidazol-1yl]methyl]biphenyl-2-carboxylic acid (telmisartan): A carboxylic acid of the general formula R1COOH, wherein R1 is the hydrogen atom or a C1-C4 alkyl, is added to a solution of the potassium salt of telmisartan in an alcohol of the formula R2OH with the water content lower than 2%, wherein R2 is ethyl or methyl.... Agent: Pearl Cohen Zedek Latzer, LLP

20100222403 - Micogel topical formulations: The present invention encompasses anhydrous micogel formulations containing miconazole and methods of use for the treatment of topical disorders including acne.... Agent: Glaxo Smith Kline C/o The Nath Law Group

20100222404 - Indazole derivative dihydrochloride: There are provided (R)—N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide dihydrochloride and a crystal thereof, and a crystal of the dihydrochloride salt having one or more major peaks at 2θ selected from the group consisting of approximately 12.8°, 21.8° and 25.0° in the powder X-ray diffraction spectrum.... Agent: Greenblum & Bernstein, P.L.C

20100222405 - Magnesium salts of hmg-coa reductase inhibitors: The present invention relates to magnesium salts of HMG-CoA reductase inhibitors, processes for their preparation, pharmaceutical compositions thereof and methods of using compositions to treat mammals suffering from hypercholesterolemia.... Agent: Ranbaxy Inc.

20100222406 - T type calcium channel blockers and the treatment of diseases: The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable... Agent: Schwegman, Lundberg & Woessner, P.A.

20100222423 - Aspalathin-like dihydrochalcone, extracts from unfermented rooibos and process for preparation: The present invention relates to a novel chemical compound of the formula I and to the pharmaceutically acceptable salts, derivatives and esters thereof. In addition, the invention also relates to a process for isolating the compound according to formula I from raw rooibos material. The present invention likewise relates to... Agent: Smith Patent Consulting, LLC

20100222422 - Dietary supplements containing extracts of aronia and methods of using same to promote weight loss: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition.... Agent: Christopher & Weisberg, P.A.

20100222424 - Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100222421 - Usage of baicalein in the preparation of a pharmaceutical composition for the treatment of traumatic brain injury: The invention provides a novel medical use of Baicalein, and in particular, a use of baicalein in the preparation of a pharmaceutical composition useful for treating traumatic brain injury. The baicalein pharmaceutical composition in this invention includes a treating effective amount of baicalein and a suitable pharmaceutically acceptable excipient or... Agent: Schmeiser Olsen & Watts

20100222425 - Compositions and treatment methods-2: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.... Agent: Harbor Biosciences, Inc.

20100222426 - Anti-bacterial agents: The invention relates to novel acylphloroglucinols which have strong growth inhibitory effects on multi-drug resistant strains of bacteria, particularly MRSA. Typically the compounds have a terpene substituent, or a terpene-derived substituent. Methods of isolating the compounds from natural sources, and synthetic methods for forming the compounds are also provided.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100222427 - Pharmaceutical composition comprising oseltamivir phosphate: The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100222428 - Fatty acid nutritional supplement: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty... Agent: Chalker Flores, LLP

20100222429 - Enzymatic methods and enzymes: Provided are methods to identify modulators and in particular inhibitors of body malodour formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodour.... Agent: Parfomak, Andrew N. Norris Mclaughlin & Marcus Pa

20100222430 - Method of treating post-surgical acute pain: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100222431 - Novel phenylurea inhibitors of the soat-1 enzyme and pharmaceutical/cosmetic compositions comprised thereof: m

20100222432 - Synthetic carbon nanotubes: Methods to prepare synthetic carbon nanotubes having controllable properties and synthetic carbon nanotubes having controllable properties are provided. The properties which are controllable using the methods provided here include independently and in combination: diameter, length, identity and number of functional groups present and identity and number of heteroatoms present.... Agent: Greenlee Winner And Sullivan P C

20100222433 - Composite disinfectant cleaner: A disinfectant cleaner is provided by combining an alkyl dimethyl benzyl ammonium chloride, an octyl decyl dimethyl ammonium chloride, a dioctyl dimethyl ammonium chloride, a didecyl dimethyl ammonium chloride, an alkylamine, a guanidine, a penetrant, a surfactant, a chelant, an essence and deionized water.... Agent: Yinping Ren

20100222434 - Pharmaceutical composition for inhibiting amyloid-beta protein accumulation: The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically... Agent: Birch Stewart Kolasch & Birch

20100222435 - Modified-release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100222436 - Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating... Agent: Morrison & Foerster LLP

20100222437 - Composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases: The invention relates to a composition comprising cannabidiol and Denbinobin and its use in medicine, for example, for the prevention and treatment of gastrointestinal inflammatory diseases and for the prevention and treatment of gastrointestinal cancers.... Agent: Moore & Van Allen PLLC

20100222438 - Methods compositions and article of manufacture for modulating bone growth: Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100222439 - Beverage containing a polymeric polyphenol: wherein the beverage has a cream inhibition (CI) of 70-100%, preferably 80-100%, wherein CI=(1−((ODS−ODB)/(ODO−ODB)))100 where ODS is the optical density of the beverage, ODB is the optical density of the tea solids in a 25% w/w aqueous solution of ethanol and ODO is the optical density of the beverage but... Agent: Unilever Patent Group

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.15547 seconds

PATENT INFO